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 Metal-based protein conjugates have become the primary means of achieving site-
specific delivery of metal ions for use in clinical applications.   Small, organic chelators are the 
primary entities used for metal delivery, but they require chemical conjugation to be attached to 
the protein surface.  Conjugation using this method requires extensive optimization and 
generates a highly heterogeneous product.  Therefore, metal-binding peptide tags capable of 
being engineered into a predetermined position, inline within a protein sequence are highly 
advantageous.  The metal-binding claMP Tag is capable of being inserted inline within a protein 
sequence to generate a “linker-less” bioconjugate.  The claMP Tag module is based upon the 
metal abstraction peptide (MAP) sequence, NCC (Asn-Cys-Cys), which has been shown to bind 
transition metals extremely tightly and to retain metal binding in the presence of longer 
polypeptide sequences, thus allowing for use of this tag as an inline metal-binding agent for the 
generation of bioconjugates.  The primary focus of this work was to characterize the effects of 
claMP Tag addition on various protein systems to establish its applicability as a metal-delivery 
platform.  Ni(II) was inserted into the tag in these studies because the Ni-claMP complex had 
previously been extensively characterized using small peptides and it was determined to be 
highly stable and to have a number of advantageous properties to enable quantitative analysis.  
The properties of this unique metal-peptide module suggested that it would be amenable to use in 
a larger protein construct, where retention of the metal would be enabling to targeted delivery. 
Herein, the unique charge, spectroscopic, and catalytic properties of the Ni-claMP complex were 
used as the basis for establishing methods to evaluate the structure and stability of claMP Tag-
based inline metal-protein conjugates.  
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Two model protein systems were chosen for analytical development that are different in 
size, composition, and structure to assess the applicability of the claMP Tag within unrelated 
proteins and using different methods of purification.  The placement of the claMP Tag within the 
protein sequence was varied to determine if tag position differentially affects metal insertion.  
Because the claMP Tag itself contains two cysteine residues, which may interfere with native 
disulfide bond formation, the first protein investigated for expression, correct folding and higher 
order structure, and stability was epidermal growth factor (EGF).  EGF is a small, difficult to 
express, disulfide-containing protein, which is capable of being produced recombinantly in E. 
coli when fused to thioredoxin, a thiol-modulating protein.  The study described herein 
demonstrates addition of the claMP Tag to either terminus of EGF does not negatively affect the 
expression or function of the protein.  NMR analysis was used to confirm that the disulfide 
bonds are formed correctly and that the tertiary structure of the protein is well maintained in the 
metal-claMP Tag conjugate.  The unique absorption spectrum and characteristic 2- charge of the 
properly formed metal-claMP structure were utilized to quantitatively assess both metal 
incorporation and stability of the conjugate.  The data show that addition of the cysteine-
containing claMP Tag to a thiol- and disulfide-containing protein does not negatively impact the 
critical attributes or protein properties, making it amenable to use as an inline metal carrier. 
 A polyhistidine tag was engineered into EGF to enable facile purification using 
immobilized metal affinity chromatography (IMAC), but this approach leads to concomitant 
uptake of Ni(II) into the claMP Tag.  To evaluate the ability to purify the tagged protein prior to 
metal insertion as well as different approaches to metal incorporation, maltose-binding protein 
(MBP) was examined.  This second protein system allows for decoupling of the metal insertion 
and purification steps because amylose resin, which does not rely on metal in any way, enables 
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affinity purification of MBP.  This allowed for metal insertion efficiencies to be determined 
before and after purification.  It also demonstrated that the claMP Tag may be successfully 
applied to larger protein systems, because MBP is approximately six-times larger than EFG.  
Finally, because of its larger size, retention of metal in the claMP Tag within the MBP variant 
could be evaluated more easily in the presence of a large excess of a potentially competitive 
high-affinity chelator.  This study was used to establish that the unique chemistry that the claMP 
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EFFECTS OF LOCALIZED INTERACTIONS AND SURFACE 
PROPERTIES ON STABILITY OF PROTEIN-BASED THERAPEUTICS 
1.1  INTRODUCTION 
Antibody drug conjugates (ADCs) are the primary means of achieving site-specific 
delivery of cytotoxic agents, but the impact of conjugation on antibody structure and stability 
may limit the molecule from making it to market.  ADCs utilize conjugation through surface-
accessible lysine residues,1-2 which alters the surface charge of the molecule, or selective 
reduction or amino acid mutation to conjugate through lysine residues.3-5  Conjugation using 
either strategy can have adverse effects on the physical stability of the molecule.  Altering the 
surface charge through lysine conjugation directly affects the stability of the molecule.1, 6 Amino 
acid mutation to achieve site-specific conjugation also causes changes in surface properties, but 
its effects on physical stability may be more drastic due to local structural changes that perturb 
the stability of the entire molecule.3-4  Because high-resolution data are difficult to obtain due to 
the large size of antibodies, mutations within smaller, therapeutically relevant proteins may be 
useful in assessing the effect of conjugation on the physical stability of the molecule.  These 
mutations are akin to large modifications required in ADCs because they both alter the surface 
properties of the molecule, which in turn affects physical stability.  Although the mechanism of 
affecting stability may not be the same in all cases, these smaller proteins can serve as model 
systems for assessing the impact of certain mutations on protein structure and stability within 
ADCs.  
Protein structure is modulated by different types of interactions among residues, with 
some interactions exhibiting greater contribution to protein structure than others.  Secondary 
structural elements, such as !-helices and "-sheets, are formed by a diverse network of hydrogen 
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bonding interactions among atoms located within the polypeptide backbone.  The hydrogen 
bonds are essential in maintaining secondary structure and a lack of hydrogen bonds is associated 
with, or may lead to, disordered structures.7  Formation of the three-dimensional fold of the 
protein requires additional interactions among amino acid side chains.  Hydrophobic association 
is critical to achieving the condensed state of a folded protein, but ionic interactions between 
charged residues on the surface of the molecule are important contributing factors in protecting 
the core to stabilize the protein fold.  Covalent bond formation between Cys side chains in the 
form of disulfide bonds cross-bridge the structure, which also can contribute significantly to the 
overall protein fold and its stability.  The core structure, packing interactions and surface 
composition impact the physical and structural stability of proteins.  The surface properties 
determine solvent accessibility to key structural elements, which contribute to the overall three-
dimensional conformation and aggregation propensity of the molecule.7  Secondary structural 
features and disulfide bonds are the main structural elements that are monitored when assessing 
changes in protein structure.  These features and changes in them are easily observed using high-
throughput approaches, which enable rapid comparison among analogs.  When coupled to 
thermal titration, this approach has been particularly useful because, as the largely hydrophobic 
tertiary contacts are broken, individual secondary structure elements are disrupted.7  Amino acid 
mutation can be used to modulate these elements to investigate contributions to stability and in 
protein engineering to generate a more stable structure.  The mutation may cause only local 
structural perturbations that lead to structural stabilization, or it may cause far-reaching 
alterations that alter the global conformation of the molecule.  Structural stabilization may be 
caused by the addition of stabilizing interactions, such as salt bridges, hydrogen bonds, or 
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hydrophobic associations; but amino acid mutation may also be destabilizing to protein structure 
due to elimination of a disulfide bond or glycosylation site.   
Addition of different entities to the protein may also be required to develop a protein 
therapeutic that exhibits the desirable pharmacological properties or therapeutic use, such as a 
drug molecule in ADC development.  A larger molecular weight species such as a polyethylene 
glycol (PEG) or lipid molecule can be attached to the protein to increase the molecular weight of 
the entire molecule, thus increasing the circulating half-life and improving the pharmacokinetics 
of low molecular weight proteins that are too quickly cleared from the bloodstream to complete 
their desired function.8-12  Addition of a PEG molecule is also desirable as it can shield regions of 
hydrophobic surface area10 or affect the ability of molecules to come in contact with each other, 
both of which increase the physical stability.  Glycans have been shown to assist in stabilizing 
protein structure13-14 by interacting with the protein directly through hydrogen bonds with the 
polypeptide backbone or through interactions with surface accessible amino acids,15-17 although 
the extent of stabilization is highly protein dependent.  Glycan and PEG molecules can also 
modulate the physical stability of the protein by shielding hydrophobic regions of the surface that 
may otherwise be prone to self-association with other protein molecules.10, 18-20  
Even though amino acid mutation and addition of larger molecules to a protein may seem 
only to have effects on nearby residues, alterations in the local structure of the protein can 
modify the global structure and physical stability of the entire molecule.  These changes can have 
detrimental effects on protein function, which is undesirable for use of a protein as a therapeutic 
entity.  As such, assessing the impact of local alterations on protein structure is critical during the 
development of protein therapeutics.  This review provides an overview of how the structural 
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stability of current protein therapeutics is affected by amino acid mutation and addition of larger 
molecules to aid in the design of ADCs with desirable structural stability. 
1.1.1  Insulin 
Insulin is a small hormone whose main function is to regulate blood glucose levels.  As a 
therapeutic entity, it is primarily used for the treatment of diabetes mellitus, which is caused by 
decreased signaling that can lead to a lack of insulin secretion.  Human insulin is a small fifty-
one amino acid globular protein that is composed of an A-chain (amino acids A1-21) and B-
chain (amino acids B1-30).  The secondary and tertiary structure of the insulin molecule is 
referred to as the insulin fold and is shared by members of the insulin fold super-family.  This 
insulin fold is composed of three !-helices, two located in the A-chain (A2-A8, A12-A19) and 
one located in the B-chain (B9-B19), and a hydrophobic core composed of nonpolar amino acids. 
Insulin is folded as a precursor protein and then cleaved to achieve the two-chain secreted form.  
Apart from the typical insulin fold, the two chains are also connected through interchain 
disulfide bonds between residues A7-B7 and A20-B19.  An intrachain disulfide bond is present 
between residues A6-A11, as well.  In addition to the three disulfide bonds, the conformation of 
the B-chain also influences the structure and bioactivity of the insulin molecule.  Insulin is 
known to have two structures characterized by two distinct B-chain conformations that determine 
the bioactivity of the molecule: the non-active R-state and the bioactive T-state.  The main 
difference between the two states is the conformation of the B1-B8 segment.  In the non-active 
R-state, the B1-B8 segment combines with the B9-B19 segment so the entire region from B1-
B19 exists in !-helical form.  The B1-B8 segment is more flexible in the active T-state as it 
adopts an extended conformation, which allows for interaction of this region with the receptor.   
! 5 
Insulin is active as a monomer, but many therapeutic versions of insulin are formulated as 
hexameric species to improve in vivo stability and generate a slower release profile.  The 
association state of the molecule is dependent on a number of factors such as temperature, ionic 
strength, protein concentration, and the presence of molecular stabilizing agents.21-24  Therefore, 
in order to evaluate the structure and solution dynamics of the monomeric form of insulin, two 
different insulin mutants have been generated that contain mutations at the dimer and hexamer 
interface: DKP insulin and 4E insulin.  The first mutant analyzed, DKP insulin, contains three 
mutations to destabilize the interface responsible for dimer and hexamer formation: HisB10Asp, 
ProB28Lys, and LysB29Pro (Figure 1.1).25-27  DKP insulin exhibits similar secondary structure to 
native insulin as determined by far-UV CD26 and NMR analysis.25, 28-29 Formation of the dimeric 
and hexameric forms of insulin occurs through coordination of Zn2+ ions by the HisB10 residues 
so mutation of this residue eliminates the coordination site,30 destabilizing hexamer formation.  
The dimer interface is also destabilized by Pro28Lys mutation because interaction of this residue 
with TyrB26 on the opposite molecule contributes to dimer stabilization, and LysB29 
participates in a network of ionic contacts to stabilize the hexamer interface.30  Computational 
modeling also shows that ProB28 has the potential to make nonpolar contacts with the backbone 
of GlyB23 and ArgB22.31  Because the combined effect of these mutations allow for reduced 
self-association propensity and these mutations do not alter the global structure of the insulin 
molecule, DKP insulin can be used to determine the effect of single amino acid substitutions on 
the local and global structure of monomeric insulin.   
In 4E insulin, PheB1, HisB10, TyrB16, and ThrB27 are mutated to glutamic acid and 
ThrB30 is removed to yield a mutant that is predominantly monomeric at millimolar 
concentrations.32   The near-UV CD and NMR spectra of this mutant exhibited similar spectral  
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features as native insulin,32-33 confirming that the protein is mainly well-ordered, except for the 
B-chain termini.32  Mutation of TyrB16 to either Glu34 or His33 results in the formation of a 
 
Figure 1.1  Mutations within dimer/hexamer interface of insulin allow for stabilization of monomeric form.  
a) P28 stabilizes dimer formation through an interaction with the peptide backbone of residues Arg22 and Gly23 
(yellow). b) His10 from each monomer contributes to chelating the metal ion required for hexamer formation. c) 
F1 makes contacts with the side chains of L13 and Y14. d) Y16 also stabilizes the dimer interface by interacting 
with Val12. e) DKP insulin contains mutations at H10, P28, and K29, which in the native molecule lead to self-
association. f) 4E insulin contains four different mutations at F1, H10, Y16, and T27 that are contact interfaces for 
self-association within the native molecule.  A-strand shown in magenta and B-strand shown in green, and the C-
terminus of the A-strand labeled to aid in visualization.  PDB files 4EWZ, 1HUI, 2JMN were used to generate this 
figure. 
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mutant that maintains native secondary and tertiary structure as determined by CD and NMR, 
respectively.  Substitution of Tyr with His results in similar denaturation stability as native 
insulin, yet this mutation is commonly used because it decreases self-association and allows for 
generation of a monomeric product at millimolar concentrations.33  Within the insulin hexamer, 
PheB1 contacts the side chains of LeuA13 and TyrA14 within the same molecule,35 and ThrB27 
side chain hydrogen bonds with the AsnA18 amide on the adjacent hexamer.30  Computational 
modeling indicates that TyrB16 has the potential to make van der Waals interaction with ValB12 
or GlyB8,31 further stabilizing the interface.  Therefore, PheB1Glu, TyrB10His/Glu and 
ThrB27Glu mutation eliminates these interactions, which destabilizes the self-association 
interface.  
1.1.2  Erythropoietin 
 Erythropoietin (Epo) is a glycoprotein hormone and cytokine that regulates red blood cell 
production.  It is used to treat anemia that results predominantly from chronic kidney failure, 
Crohn’s disease, or chemotherapy.36  This glycoprotein consists of 166 amino acids and four 
carbohydrate motifs, three N-linked (Asn24, Asn38, Asn83) and one O-linked (Ser126), that 
account for nearly 40% of the molecule by weight.  The primary role of the carbohydrate chains 
is to stabilize protein structure to limit self-association, but they also have been shown to affect 
the in vivo activity of the protein.18  The solution structure of Epo shows that it contains the left-
handed four-helix bundle commonly observed in cytokines.37  The four helices are denoted as 
Helix A, Helix B, Helix C, and Helix D and exhibit an up-up-down-down direction.37  The 
helical components of Epo are very important in maintaining the global conformation and 
bioactivity,38  whereas modifications in the regions between the helices, known as 
interconnecting loops, do not impact the structure of the protein as drastically.39-42  Three 
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different loops of varying sizes are present in Epo: the AB loop consists of 36 amino acids, two 
N-glycosylation sites, and a disulfide bond between Cys29-Cys33, the BC loop is smaller in size 
at only five residues in length, and it contains the third N-glycosylation site, and the CD loop 
contains 23 amino acids and the O-glycosylation site.  An additional disulfide bond is present 
between Cys7-Cys161 that is responsible for maintaining the global structure as it connects 
Helix A and Helix D.  The implications of modifying these structural elements on molecule 
stability will be discussed later in this review.  
1.1.3  Interferon  
 Interferons are glycoprotein cytokines that are produced by the body in response to the 
introduction of pathogens such as bacteria or viruses.  The Type I interferons, IFN-! and IFN-", 
exhibit antiviral, antiproliferative, and immunomodulatory functions, which has led to their 
development into protein therapeutics.43-46  IFN-!-2 is primarily used for the treatment of 
different viral diseases47 and IFN-"-1 is used in the treatment of multiple sclerosis,19, 48-52 whereas 
both have been useful in the treatment of cancer.  Similarly to Epo, IFN-!-2 and IFN-"-1 exhibit 
the four-helix bundle with up-up-down-down topology that is commonly found in cytokines.15, 53-
54  Both also include a fifth helix that is not involved in the four-helix bundle, but still contributes 
to the overall structure of the protein.  Apart from containing a similar helical topology, the 
primary sequence of the two is quite different with only approximately 50% amino acid 
homology between the two.55-56  This difference in amino acid composition leads to differences in 
the disulfide network and glycosylation pattern.  IFN-!-2 is a 165 amino acid protein that 
contains two disulfide bonds between Cys1-Cys98 and Cys29-Cys13857 and an O-glycosylation 
site at Thr106.58  On the other hand, IFN-"-1 contains 166 amino acids, one disulfide bond 
between Cys31-Cys141, and a N-glycosylation site at N80. 
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 Two IFN-" variants exist, IFN-"-1a and IFN-"-1b, with the primarily difference between 
the two variants reliant upon the expression host used to produce the two molecules.  IFN-"-1a is 
the form found in the human body so it is glycosylated at Asn80 and as a therapeutic entity, must 
be produced in a host capable of performing glycosylation.  The IFN-"-1b form is a recombinant 
version produced in an E. coli-based system, thus it is not glycosylated.  It also lacks the N-
terminal Met residue and has a Cys17Ser mutation to assist in obtaining the correctly folded 
form.  Even with these two alterations, the structure of the two IFN-" variants are expected to be 
very similar because the mutated Cys residue is not involved in the formation of any disulfide 
bonds.19, 59  On the other hand, the stability of the two variants differs due to the presence of the 
glycan group in the IFN-"-1a variant and its absence in IFN-"-1b.60-61 The glycan shields an 
uncharged region located on the surface of the molecule and directly interacts with nearby 
residues to increase the solubility and structural stability of IFN-"-1a over the non-glycosylated 
variant, IFN-"-1b.19, 61  
1.2  MODULATION OF STRUCTURAL ELEMENTS THROUGH MUTATION OR 
DISULFIDE BOND REARRANGEMENT  
1.2.1  Mutations that Alter Hydrophobic Interactions 
 The likelihood of amino acid side chains to associate with water is a primary factor 
governing protein folding and physical stability.  Nonpolar amino acids are preferentially 
excluded from the protein surface,!62-65 resulting in hydrophobic association among these residues 
to form the core of the molecule and drive the formation of the tertiary structure.  Therefore, 
mutation of residues that contribute to the hydrophobic core would be expected to alter the 
structure and stability of the molecule.  The degree of alteration, though, depends on the amount 
of energy contributed to maintaining the core of the molecule, which varies with the extent of 
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hydrophobic surface area and aromatic character.  In 4E insulin, ValA3Gly and ThrA8His/Arg 
mutation results only in local structural alterations that have opposite effects on the hydrophobic 
content of the region.66  ValA3Gly substitution results in complete loss of the !-helical character 
in the A2-A8 region (Figure 1.2), which leads to decreased hydrophobic surface area in this 
region due to elimination of the ValA3 side chain and shifting of the GluA4 side chain to 
encompass a region of the protein that was predominantly hydrophobic in nature in the native 
structure.66  Mutation of ThrA8 to His or Arg, though, leads to tightening of the A2-A8 !-helix, 
and increased exposure of the hydrophobic residues IleA2 and ValA3,66 without adversely 
affecting the global structure.  The A3 mutations within DKP insulin also suggest that nonpolar 
 
Figure 1.2  A3 and A8 mutations affect helicity of local segment.  Mutation of ValA3 or ThrA8 only 
cause local structural alterations in the A2-A8 helix of the A-chain (boxed).  Whereas ValA3Gly 
mutation eliminates helical feature, ThrA8His/Arg mutation leads to tightening of the helix.  
Reproduced with permission from Olsen, H. B., Ludvigsen, S., Kaarsholm, N. C. (1998) The 
relationship between insulin bioactivity and structure in the NH2-terminal A-chain helix. J. Mol. Biol. 
284, 477-488, # 1998 Elsevier, Philadelphia, PA.  
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interactions are essential for maintaining structural stability.  Although ValA3Thr mutation did 
not affect protein conformation, it did alter the denaturation stability of the molecule due to the 
introduction of a polar moiety in a region of high hydrophobicity,67 which alters the packing 
efficiency and solvent accessibility in the region.   
Even if a residue seems to contribute minimally to protein structure and the hydrophobic 
core of the molecule, it may exert a large effect on protein structure by protecting buried, 
stabilizing interactions.  Elimination of the protection provided by specific residues leads to 
greater solvent accessibility and disruption of the stabilizing interaction, which adversely affects 
protein stability.68  Within insulin, PheB24 is important for maintaining the hydrophobic core of 
the molecule as it packs against other nonpolar residues such as ValB12, LeuB15, and the A20-
B19 disulfide bond in both crystal structures and in solution.21, 25, 28-30, 69-70  Substitution of this 
residue with non-aromatic L-amino acids, such as Ser or Leu, and aromatic residues, such as His, 
alters the solution structure of the molecule, which leads to decreases in bioactivity.26, 71-72  In the 
PheB24His mutant, the His side chain is more tightly packed into the B24 hydrophobic pocket 
than Phe due to the ability to form additional hydrogen bonds.72  The PheB24 to Gly mutation 
also drastically decreases the folding stability of the molecule.  NMR illustrates that the core 
structure and !-helical content of the PheB24Gly mutant remain, but the mutant is more flexible, 
which leads to instability and unfolding of the B20-B30 region.34, 73  Within Epo, mutation of 
Gly151, which contributes substantially to core formation by bringing the side chain of Lys152 
into contact with Val63, Trp51, and Phe148,37 results in global rearrangements within the 
hydrophobic core of the molecule.74  In addition to maintaining the core of the molecule, 
hydrophobic residues are also important for forming interactions that stabilize different domains 
of Epo.  Mutation of Helix B residues Leu69, Leu70, and Ala73, which make important 
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hydrophobic contacts with Ile39 and Val41 of the AB loop,37 alters protein conformation.  
Leu69Ala resulted in only slight conformational changes, whereas Leu70Ala, but not Leu70Ile, 
substitution resulted in drastic conformational changes,74 illustrating the necessity of a larger 
nonpolar side chain at this position.  Substantial conformational changes are also observed upon 
substitution of Val63, Leu67, and Val74 with Ser.74  Val63, Leu67, and Val 74 are buried within 
the helices and appear to make hydrophobic contacts holding the helices together thus 
confirming their importance.37  
The presence of aromatic side chains, as opposed to solely hydrophobic side chains, may 
be necessary to form the most stable structure.  Within insulin, removal of the aromatic side 
chain of PheB1 eliminates the packing interaction with LeuA13 and causes destabilization of the 
B1-B4 region.33  Mutation of TyrB26 to Thr also leads to a decrease in folding stability due to 
the elimination of stabilizing aromatic interactions.75  The importance of aromatic interactions in 
maintaining global structure is also observed within Epo and the interferons.   The aromatic side 
chains of Phe142/Tyr145 and Phe148/Tyr156 interact with hydrophobic residues located on the 
AC and BC helix, to form the hydrophobic core of the Epo molecule (Figure 1.3).37  Substitution 
of these residues leads to disruption of the core, leading to protein unfolding.74  Mutation of 
Phe142 to Ile causes slight perturbations in global conformation, whereas mutation of Tyr145 to 
either Ile or Phe causes substantial conformational rearrangements.74  Therefore, Phe142 must 
primarily make hydrophobic interactions so Ile will not alter the structure, but placement of Tyr 
at position 145 is necessary for both aromatic interactions, as determined by the Ile substitution, 
as well as a type of dipole interaction or stabilizing hydrogen bond because substitution with Phe 
at this site also resulted in conformational rearrangement.  Phe148Val or Tyr156Ile/Phe mutation 
confirms that a larger hydrophobic entity is required at this site because Val/Ile substitution 
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results in substantial alterations in global conformation, but Phe substitution does not and is still 
successfully secreted.74, 76-77  Substitution of Phe148 to Tyr results in a slight conformational 
change,74 which could be caused by the addition of the hydroxide moiety into the hydrophobic 
pocket, whereas elimination of the moiety in the Tyr156Phe substitution would not be expected 
to alter the structure of the core.  
As the exposure of nonpolar side chains to a water-based environment is unfavorable and 
destabilizing,25, 29 substitution of a solvent-exposed nonpolar side chain for a more polar residue 
decreases the exposed hydrophobic surface area and increases the physical stability.  
Introduction of Asp, His, or Ser into the B25 position of insulin leads to an increase in the 
 
Figure 1.3  Four aromatic residues within Epo make large contributions to protein core.  Substitution of the 
four primary residues responsible for maintaining the hydrophobic core leads to substantial conformational 
rearrangements.  PDB file 1BUY was used to generate this figure.  
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folding stability due to subtle rearrangements in the global structure.26, 75  The side chain of 
PheB25 is pointed toward the solvent, suggesting that it does not contribute significantly to 
maintaining protein structure, thus implying that the increases in folding stability are due to the 
elimination of hydrophobic surface area.  The introduction of a polar side chain into the 
hydrophobic core will have the opposite effect and destabilize protein structure, as is illustrated 
by the conformation changes observed within Epo upon substitution of the core residues Ala98 
or Leu105 with Ser.74  The Leu105Asp mutation causes even more drastic conformational 
changes than the Leu105Ser mutation,74 suggesting that, as expected, the core of Epo is more 
destabilized by introduction of a charged residue than simply a polar residue.  Charged residues 
are more water-soluble than polar residues and in order for these to be stably contained within 
the hydrophobic core, salt bridges and/or hydrogen-bonding requirements must be satisfied.78-81  
Structural rearrangements in the four-disulfide insulin mutant (4SS-insulin) lead to a drastic 
decrease in the solvent-exposed hydrophobic surface area due to mutation of the hydrophobic 
residue Ile to Cys and additional shielding of hydrophobic residues,82 thus increasing the physical 
stability of the monomer.  The Tm of the four-disulfide mutant is 34.6 °C greater than that of 
native insulin, and extensive shaking for forty-five hours shows complete fibrillation of the 
native molecule, whereas the four-disulfide mutant exhibits none,82 illustrating that 
improvements in physical stability can be made by decreasing exposed hydrophobic surface area.   
1.2.2  Mutations that Affect Net Surface Charge 
Charged residues help stabilize protein structure through electrostatic interactions that 
pair residues of opposite charge.  This can be accomplished on the surface of the protein79, 83-84 or 
in the form of internally buried salt bridges.79, 85  Because these interactions contribute to local 
structural elements within domains or assist in structure formation by connecting different 
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domains, mutation of these residues can cause substantial conformational changes.  Large 
changes in protein conformation have been observed due to electrostatic repulsion when an 
oppositely charged residue is introduced in close proximity to a similarly charged residue.  The 
extreme case of this effect is apparent in many intrinsically disordered proteins (IDPs).  Within 
Epo, the alterations in the three-dimensional fold observed upon Gln78Glu, His94Glu, or 
Lys97Glu/Asp substitution74 are due in part to charge repulsion between Glu78 and Asp96, 
Glu94 and Glu18 or Glu21, and Glu/Asp97 and Glu18 or Glu21 (Figure 1.4).  Ala substitution at 
position 78 or 97 results in slight structural changes,74 suggesting that the substantial alterations 
in protein conformation observed upon introduction of Glu in these regions are not solely due to 
charge repulsion, but may also be caused by the elimination of stabilizing interactions such as a 
 
Figure 1.4  Alterations in the three-dimensional fold of Epo are caused by 
charge repulsion.  Mutation of residues shown in red to Glu causes conformational 
changes because it leads to similarly charged residues within close proximity, 
which will cause charge repulsion and structural alterations.   PDB file 1BUY was 
used to generate this figure. 
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hydrogen bond or salt bridge.  Within IFN-!-2, mutation of Lys31, which works cooperatively 
with Lys133 to sandwich the side chain of Asp32,53-54 to Glu causes conformational changes that 
lead to large changes in the bioactivity.86  Introduction of a charged side chain in close proximity 
to similarly charged amino acid would be expected to alter the global conformation of the 
molecule due to repulsion of the similar two side chains.  
Mutations that lead to elimination or addition of ionic interactions are destabilizing and 
stabilizing for protein structure, respectively.  Charged residues within the B20-B23 loop of 
insulin stabilize the tertiary conformation by forming electrostatic interactions with C-terminal 
A-chain residues to correctly orient the two chains of the molecule.  Removal of these 
interactions through mutation of GluB21 or ArgB22 to Ala results in a 25% decrease in protein 
expression levels relative to native insulin,87 confirming that interactions within this loop are 
important in maintaining protein structure.  The global structure of Epo is also substantially 
altered upon elimination of a charged residue (Glu23Ser)"74  As Glu23 is buried between the A 
and D helix interface,37 and appears to form a salt bridge with a residue located on the D helix, 
Ser substitution eliminates this potential interaction.  The results observed with insulin and Epo 
confirm the importance of salt bridges in maintaining protein structure.  In contrast to the 
destabilizing effects observed by salt bridge elimination, addition of a non-native salt bridge 
through amino acid mutation is stabilizing to protein structure.  Deletion of ThrB27 within 
insulin causes rearrangements that position the side chains of LysB29/GluA4 and the N-terminus 
of the A-chain and C-terminus of the B-chain in close proximity of one another.  Therefore, the 
increase in folding stability observed with this mutant may be caused by the addition of two non-
native sites for ionic interactions to occur.75  Modulation of the thermal stability of Epo has been 
investigated by mutation of Arg103.  Ala substitution causes minimal impact on protein 
! 17 
structure,74, 88 whereas introduction of a negatively charged side chain through Glu/Asp mutation 
results in a substantial increase in thermal stability.88-89  Multiple mutations were tested at this 
site to determine their effect on thermal stability with Asn, Asp, and Glu substitution increasing 
the stability, Ala and His substitution having similar stability as the native molecule, Gln 
substitution slightly decreasing the stability, and Lys substitution substantially reducing the 
stability.89  Even though a few positively charged residues were located nearby, the exact 
interaction(s) responsible for the observed increase in thermal stability is undetermined.89  
Charged residues can exert a field effect in which one charged moiety interacts with several 
oppositely charged residues within the bonding radius to further stabilize the protein 
conformation.  
The physical stability of protein therapeutics can also be improved by increasing the 
number of charged residues on the protein surface.  This principle has been applied to non-
glycosylated Epo, which has a lower stability than its glycosylated counterpart.18  Mutation of the 
N-glycosylation sites to Lys results in the formation of a mutant with the same structural 
properties as native Epo produced in E. coli,12, 34, 35 but improved thermal structural and 
aggregation stability and solubility in comparison to native, non-glycosylated Epo.18, 37, 90  The 
denaturation stability of the two variants is very similar, and the observed melting temperature 
was also determined to be scan-rate dependent.90  The data suggest the increase in net charge 
does not necessarily rigidify the protein fold to impart stability; rather, it alters the temperature-
dependent aggregation kinetics of the unfolded state by decreasing the aggregation rate for the 
Lys mutant in comparison to the native protein.90  
Akin to mutation, chemical modification alters the surface properties of a protein.  
Although the compounds attached induces a significantly larger change in size than mutation, 
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chemical principles still apply.  The most noted property is decreased solubility, due to the 
relatively more hydrophobic character of the linkers and drugs.  Self-selection occurs, where 
higher drug-to-antibody ratio (DAR) species precipitate during the reaction, such that an average 
DAR is typically below 4.  The net surface charge commonly becomes more negative upon 
formation of conjugates because the most commonly used method relies on coupling to surface 
exposed lysine residues, incorporating the basic amine into a neutral amide bond.  In addition to 
generating a heterogeneous mixture of molecules, multiple charge states have been observed 
with modification of a single lysine, depending on the position of the residue within the protein 
structure,91 further complicating structural analysis.  In some cases, this may be due to the 
formation of different chemical isomers upon linking at the same residue.  Conjugation to lysine 
residues may also impart structural modifications that negatively impact the physiochemical 
properties of the molecule.  Addition of the drug entity to lysine residues in T-DM1 caused 
destabilization of the structural stability of the CH2 domain, which is the least stable domain in 
antibodies and is where the majority of conjugation occurs.2  Alterations in the structure of this 
single domain led to decreased thermal stability of the entire conjugate in comparison to the 
parent antibody.1  Although lysine conjugation was shown to alter the thermal stability of T-
DM1, it has a more limited effect on thermal stability than thiol conjugation.6  This difference 
may be due to the more severe structural alterations caused by modification of cysteine residues, 
which is discussed later in the manuscript.  In both cases, the number of drug molecules attached 
is low, particularly with respect to the large size of an antibody and the high number of basic 




1.2.3  Mutations that Alter Hydrogen Bond Formation  
Amino acid mutation may also result in the introduction of non-native hydrogen bonds 
that stabilize protein structure.  In native insulin, PheB25His/Ser mutation leads to an increase in 
folding stability due to subtle structural rearrangements that allow for the formation of an 
additional hydrogen bond between the substituted residue and TyrA19,26, 75 thus stabilizing 
protein structure.  ThrA8His/Arg mutation also introduces an additional hydrogen bond within 
insulin between A8 and GluA4.  A hydrogen bond at this location is not present in native insulin 
because it would result in exposure of the nonpolar portion of the Thr side chain to water, which 
is highly unfavorable.75  This additional hydrogen bond present in the mutant tightens the helix, 
not altering the global conformation, but increasing the folding stability of the molecule.66, 75 This 
mutation also enhances insulin activity 3-fold,66, 75, 92 as changes in the conformation of the A2-
A8 helical region has been shown to greatly impact insulin potency.66, 93  The importance of 
hydrogen bonds in maintaining the active conformation has also been illustrated within IFN-"-1; 
Arg147Ala substitution, which eliminates a crucial hydrogen bond between Arg147 and Leu24 
responsible for stabilization of the AB loop,15 causes changes in conformational leading to 
decreased function.94  Therefore, modulation of the hydrogen bonding patterns within crucial 
structural elements, such as the A2-A8 !-helix within insulin, can be used to develop molecules 
that exhibit both high structural stability and bioactivity (Figure 1.2).     
Addition of hydrogen bonds can also lead to increases in structural stability of therapeutic 
proteins.  HisB10 is mutated to form the 4E and DKP insulin molecules discussed earlier as 
mutation of this residue leads to reduced self-association and generation of monomeric species.  
Mutation of HisB10 to either a Glu or Asp introduces the potential for another hydrogen bond 
within the molecule between the carbonyl oxygen of the side chain of the substituted residue and 
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the backbone amide NH of CysB7 
(Figure 1.5).  The additional 
interaction leads to large increases in 
the chaotropic denaturation stability 
of the molecule75 and stabilization of 
structural motifs required for high 
affinity receptor binding.26, 75, 95  Even 
though HisB10Thr mutation also 
provides the potential for a similar 
stabilizing hydrogen bond, Thr 
substitution decreases the 
denaturation stability because 
formation of the hydrogen bond 
leaves the methyl side chain of Thr exposed to solvent, which is highly unfavorable and 
deleterious to protein stability.75  The thermal stability of insulin can also be increased through 
the addition of non-native hydrogen bonds.  Introduction of a fourth disulfide bond within insulin 
(A10/B4) results in the addition of at least four non-native hydrogen bonds and increases the Tm 
by 34.6 °C,82 confirming the importance of hydrogen bonds and disulfides in modulating the 
structural flexibility that can directly impact the stability profile of protein therapeutics. 
1.2.4  Mutations that Eliminate Evolutionarily Conserved Amino Acids 
Evolutionarily conserved residues are commonly mutated to determine the exact role of 
these residues in protein structure.  Within insulin, mutation of LeuB6 with Gly, Ala, Met, Val, 
or Phe does not alter the secondary structure, but does change the bioactivity of the molecule 
 
Figure 1.5  HisB10Glu mutation within insulin introduces 
additional hydrogen bond.  Mutation of HisB10 to either Glu 
or Asp introduces the possibility of an additional hydrogen 
bond within the molecule between the side chain of Glu/Asp 
and the backbone amide NH of CysB7.  PDB file 1HUI was 
used to generate this figure.  
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with the extent of alteration dependent on the size and hydrophobicity of the substituted 
residue.93  As discussed earlier, the B1-B8 region of the insulin molecule determines whether the 
molecule exists in the R- or T-state.  The increased flexibility of the T-state is necessary for high 
affinity interactions of residues within this segment with the receptor.  Therefore, the decreased 
bioactivity observed with mutation of LeuB6 suggests that local alterations in structure occur 
without affecting the secondary structural elements.  For example, substitution with Met 
increases the bioactivity more than Gly substitution, suggesting that an increase in the size and/or 
decrease in flexibility of the B6 residue positively contributes to maintaining the bioactive 
conformation.93  From these mutations, several different roles of LeuB6, such as correctly 
orienting the amino-terminal portion of the B-chain relative to the rest of the molecule, were 
hypothesized.87, 93  Results of investigations into the effects of these mutations on the local 
structure of the insulin molecule are not yet available but could provide needed insight into the 
structural alterations that occur to accommodate the substituted residues and how these changes 
impact the stability of the molecule.   
In addition to modulating bioactivity, mutation of evolutionarily conserved residues can 
also impart structural changes that alter the folding and stability of the molecule.  Mutation of 
GlyB8 to Ala would not seem to impart much difference with regard to structure because it 
simply introduces a methyl group, but this mutation causes 2-3 fold decreases in refolding 
yield.96 Similar decreases in refolding yields are observed mutation of GlyB8 to Ser, Thr, or 
Leu.97  The refolded mutants also exhibit reduced !-helical character, with the largest 
modifications caused by the Ser and Thr mutations.  Denaturation-induced unfolding confirms 
that substitution with Ser, Thr, or Ala leads to the generation of the most structurally unstable 
molecule as the denaturant concentration needed for unfolding was decreased by 15%, whereas 
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Leu had a very similar midpoint as native insulin.96-97  The presence of a Gly residue at the B8 
position is essential for achieving the desired structural stability due to the nature of the dihedral 
angle required at this position to maintain the B7-B10 turn within the T-state of insulin.98  The 
mutants are also much more easily reduced than the native form,96-97 which would be expected 
because GlyB8 is directly adjacent to the A7-B7 disulfide bond and structural alterations caused 
by mutation of GlyB8 would be expected to cause differences in disulfide stability.  
1.2.5  Deletion of Segments of Protein Sequence 
Deletion of multiple sequential amino acid residues can have varying effects, which are 
dependent on the role of these residues in maintaining protein structure, as well as the size of the 
deleted segment.  Although it is difficult to elucidate the exact residue responsible for changes in 
protein structure or stability when multiple residues are eliminated, general trends can be 
established.  For example, NMR confirms that deletion of the B25-B30 region in insulin does not 
alter the tertiary structure of the molecule.21, 100-101  Deletion of this region does lead to a decrease 
in denaturation folding stability75 and alterations in the molecular dynamics of the mutant,25 
suggesting that the structural stability of the molecule is altered by deletion of this segment.  The 
results from Epo mutants are more difficult to interpret.   Although deletion of segments within 
the Epo sequence have been shown to affect protein secretion with the extent dependent on the 
deleted segment,40 the differences in secretion efficiency may be reflective of cellular processing 
issues, as opposed to structural instability.  Therefore, results based on deletion of multiple 
residues should not be used to draw conclusions about the molecule’s structural stability because 
these mutations cause many different opportunities for structural change that are difficult to 
interpret.   
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1.2.6  Modulation of Native Disulfide Network 
1.2.6.1  Elimination of Disulfide Bonds 
Each disulfide bond within a protein exhibits differential effects on the folding efficiency 
and structural stability of the molecule, depending on extent of contribution of the bond to 
protein structure.  The interchain disulfide bonds of insulin have a greater effect on the folding 
efficiency than the intrachain bond.  Deletion of the intrachain disulfide bond through Cys to Ser 
mutation, referred to as the A6-11 mutant, results in a 25% decrease in folding efficiency, 
whereas deletion of the interchain disulfide bonds A7-B7 and A20-B19 through Cys to Ser 
mutation, referred to as the A7-B7 and A20-B19 mutants, substantially decrease the folding 
efficiency by 46% and 72%, respectively.27, 99-100  Refolding of each mutant containing two of the 
three native disulfide bonds yields a mixture of misfolded monomer and cross-linked multimers, 
but it is possible for correct formation of the remaining two disulfide bonds to occur with 
minimal impacts to secondary structure.99, 101-103  Removal of any of the three disulfide bonds 
causes increased structural flexibility and unfolding with the A20-B19 mutant exhibiting the 
greatest extent of unfolding.99-100, 102  The A6-A11 and A7-B7 mutants contain 25% helical 
content with respect to native insulin with structural rearrangements only observed locally in the 
A-chain, but elimination of the A20-B19 disulfide bond results in complete abolition of any 
helical character.27, 99-100, 104-105  Similarly to the A20-B19 disulfide bond within insulin, one 
disulfide bond within Epo and IFN-!-1 is more critical for preserving protein structure than the 
other.  Because the Cys7-Cys161 disulfide bond of Epo connects Helix A and Helix D, which is 
required for formation of the up-up-down-down topology, deletion or mutation of either Cys7 or 
Cys161 causes drastic alterations in the tertiary structure.39, 74  On the other hand, the Cys29-
Cys33 disulfide bond is not a strong contributing factor in determining the topology of Epo as 
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replacement of either Cys29 or Cys33 with Tyr results in the successful secretion.39  Within IFN-
!-1, the Cys29-Cys138 disulfide bond contributes greater to maintaining the global 
conformation, as the presence of this disulfide bond alone, but not Cys1-Cys98, is sufficient for 
maintaining the biological activity of IFN-!-2.106  Because the AB loop is important in 
maintaining the biologically active conformation,94, 107 deletion of this disulfide bond, which 
connects loop AB and Helix E,53-54 will result in global structural rearrangements that are highly 
detrimental to bioactivity.  IFN-"-1 contains only one disulfide bond that is responsible for 
connecting the AB loop and Helix E,15, 108 which is essential for biological activity.46, 109  
Elimination of this disulfide bond through Cys141Tyr mutation results in complete loss of 
biological function,108 suggesting that large structural rearrangements occur in the absence of this 
bond. Further mutagenesis studies could provide insight into whether it is possible to introduce 
stabilizing interactions within the proteins discussed to stabilize the native conformation in the 
absence of a disulfide bond.   
Because disulfide bond removal eliminates key components of protein structure, the 
stability of these mutants would be expected to be less than that of the native molecule.  Current 
work suggests that the A7-B7 insulin mutant exhibits a severe loss in ordered structure within 
only the A-chain and is more easily unfolded by denaturant and temperature in comparison to the 
A6-A11 mutant.27  The decreased folding stability could be due to the increase in exposed 
hydrophobic surface area on the A7-B7 mutant,99-100 which makes it more prone to undergo 
unfolding or an association-induced unfolding event.  The A20-B19 mutant was also more easily 
unfolded by denaturant and exhibited an increase in molecular hydrodynamic volume,99 
suggesting that elimination of this bond causes structural instability.  The thermal stability of 
IFN-!-2 is also altered in the absence of the disulfides.  It was reported that incubation of a 
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chemically reduce, disulfide-free mutant at 25  °C does not infer conformational changes and the 
disulfides can be reformed, but incubation of the mutant at 37 °C eliminates the native structure, 
does not allow reformation of the disulfides using thiol exchange, and results in the formation of 
HMWS and visible precipitation.106  The elevated temperature could promote conformational 
changes, followed by aggregation, or it could increase the aggregation rate and drive the 
conformation change.   
Elimination of disulfide bonds has also been shown to increase protein stability.  In 
phosphatase of regenerating liver (PRL-1), the reduced form of the protein exhibits higher 
physical stability than the oxidized form.68  Elimination of the disulfide leads to local structural 
alterations near these Cys residues, which allows for the formation of an additional, stabilizing 
hydrogen bond.  Disulfide bond elimination within Hsp16.3 has also been shown to increase the 
stability of the molecule.110  In this case, formation of the disulfide causes undesirable 
conformational rigidity and increased hydrophobic surface area, which leads to protein self-
association and aggregation.110  Therefore, the effect of disulfide bond elimination on molecular 
stability is dependent on both local and global structural changes that occur in the absence of the 
bond.   
Modulation of disulfide networks is also performed in the generation of ADCs.  Drug 
conjugation to native cysteine residues can be performed after breaking intermolecular disulfide 
bonds made accessible through selective reduction.3-4  Non-covalent interactions maintain the 
structure near the hinge region in the absence of the disulfide bonds,111 but the greater 
fragmentation rates observed at higher ionic strength confirm that these interactions are not 
sufficient to maintain protein structure.3   Even though the quaternary structure is well-
maintained, elimination of these structural features and introduction of a hydrophobic entity at 
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the site could cause local structural changes that cause the molecule to be more susceptible to 
unfolding when thermally stressed.4  The rapid aggregation of cysteine-conjugated ADCs and 
lower Tm of the CH2 domain indicate that structural alterations have occurred within the 
molecule,3-4 although they may be not be observable with low resolution techniques such as CD.  
It is suggested that the CH2 domain is the cause of aggregate formation due to its instability in 
the absence of the disulfides and its presence as a partially unfolded domain within the 
aggregate.4  The number of conjugated entities or DAR has also been shown to influence the 
physical stability of the molecule, confirming that the decreased physical stability of ADCs is 
due to both elimination of disulfides and introduction of a hydrophobic entity on the surface of 
the protein structure.  Conjugation at Cys occurs preferentially within the Fab region for the 
lower DAR species (2-4), whereas the higher DAR species are conjugated at both the Fab and 
hinge region.  The decrease in Tm observed within higher DAR conjugates suggests that the 
number of drug entities, as opposed to disulfide elimination, causes the largest impact on protein 
structure.  Unfolding of the CH2 domain has also been observed at low DAR,3 where 
conjugation primarily occurs in the Fab region, illustrating the far-reaching effects that surface 
modification can have on the structural stability of ADCs.  
1.2.6.2  Addition of Cysteine Pairs 
In addition to disulfide bond elimination, non-native disulfide bonds have also been 
introduced to determine their effect on protein structure and stability.  Using the high-resolution 
structure, cysteine residues can be introduced into precise locations within the protein structure 
that are favorable and don’t affect the native disulfide bonds.  Addition of a third interchain 
disulfide bond in insulin between residues A10 and B4 (4SS-insulin) minimally alters expression 
levels,82 the structure of the four-disulfide mutant is altered.  The additional disulfide bond 
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constrains the N-terminal portion of the 
B-chain in a conformation that does not 
allow it to achieve the R-state and leads 
to the formation of a non-native "-
sheet between A10-A12 and B2-B4 
(Figure 1.6).82  Structural 
rearrangements in the four-disulfide 
insulin mutant (4SS-insulin) lead to a 
drastic decrease in the hydrophobic 
surface area as discussed earlier, and 
formation of addition hydrogen bonds 
between the A- and B-chain, which 
cause the 4SS-insulin mutant to exhibit 
a Tm 34.6 °C greater than that of native 
insulin.82   
Rearrangement of the non-
essential disulfide bond within Epo also leads to stabilizing modifications in protein structure.  
Epo(NDS) contains four mutations (His32Gly, Cys33Pro, Trp88Cys, and Pro90Ala) that 
rearrange the disulfide bond from Cys29-Cys33 to Cys29-Cys88, thus connecting the AB and 
BC loops.112  The Fc-Epo(NDS) fusion protein exhibited better folding with 93% monomer 
observed in the NDS mutant and only 65% monomer content in the native counterpart.112  In the 
solution structure, Cys29 is very near in space to Trp88 so formation of a disulfide bond at this 
location stabilizes Helices A and C in the four-helix bundle.  The His32Gly and Pro90Ala 
 
Figure 1.6  Addition of a non-native disulfide within 
insulin increases thermal stability.  With the mutation of 
A10 and B4 to Cys, an additional disulfide bond is formed 
between the two strands leading to additional hydrogen 
bonding interactions.  These additional stabilizing 
interactions drastically increase the Tm of the mutant.  
Modified and reproduced with permission from Vinther, T. 
N., Norrman, M., Ribel, U., Huus, K., Schlein, M., 
Steensgaard, D. B., et. al. (2013) Insulin analog with 
additional disulfide bond has increased stability and 
preserved activity. Protein Sci. 22, 296-305, # 2013 John 
Wiley & Sons, Inc., Hoboken, NJ. 
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mutations alleviate structural strain near the BC loop caused by the new disulfide bond, with the 
Pro90Ala mutation contributing greater to expression of the protein in a non-aggregated state.  
The Epo(NDS) mutant also exhibited a 20-fold greater resistance to enzymatic cleavage than 
native Epo in the absence of glycosylation.112  Although the reason for the increased stability is 
not fully understood, it is suggested that the NDS mutant is packed more tightly than the native 
protein which decreases water accessibility into the core.112   
Engineered disulfide bonds have also served useful in increasing the thermal stability of 
antibody fragments113-116 and whole antibodies.  For example, modulation of the disulfide 
network within the Fab domain of IgG4 leads to increased thermal stability of the entire 
antibody.117  Although the Fab domain of IgG4 has a drastically lower thermal stability than 
IgG1,118 altering the interchain disulfide pattern of IgG4 (DSB between LC Cys214 and HC 
Cys229 as opposed to HC Cys214) to be more similar to that of IgG1 increases the thermal 
stability of IgG4 to similar values observed for IgG1.  Although CD analysis illustrates that 
minimal structural changes accompany these substitutions, this low-resolution method is not 
sufficient to probe how local structural perturbations cause increased thermal stability.  
Additional investigation into the physical stability of the disulfide-mutants could provide details 
regarding the key structural interactions necessary for stabilization, and if the potential exists to 
further modulate the disulfide network of other therapeutic proteins to increase their physical 
stability.  
Disulfide bonds are commonly engineered into protein structures to increase the 
structural stability of the molecule, but introduction of a non-native disulfide bond can also have 
a destabilizing effect on protein structure.  Although molecular modeling can provide a good 
assessment of the optimal location of an engineered disulfide within the protein structure, the 
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theoretical results do not always align with what is observed experimentally, leading to structural 
destabilization.119  Introduction of a non-native disulfide bond can lead to elimination of crucial 
stabilizing interactions, such as hydrogen bonds, or cause atypical dihedral angles, both of which 
will have a destabilizing effect on protein structure.120-121  Engineered disulfide bonds have also 
been shown to stabilize local stability, whereas the global stability of the molecule was 
decreased.122  In this case, the non-native disulfide bond stabilized the denatured state, which 
decreased the stability of the entire molecule.  The stabilization or destabilization effect observed 
upon introduction of non-native disulfide bonds is dependent upon the structural elements altered 
by introduction of the disulfide.  Many of the engineered disulfide bonds that induce structural 
stabilization link regions between 25 and 75 residues apart that exhibit high conformational 
mobility.123  Improvements in thermal stability have also been observed through engineering of 
disulfide bonds into regions of high flexibility.124-125  The stabilizing effect of disulfide bonds is 
caused by a decrease in the conformation entropy of the unfolded state.123, 126  Therefore, 
engineered disulfide bonds lead to structural stabilization by increasing the structural rigidity of 
the molecule, but can also eliminate crucial stabilizing interactions and destabilize protein 
structure. 
1.3  MODULATION OF STABILITY THROUGH CHEMICAL MODIFICATION 
 Chemical modifications such as glycosylation and PEGylation impact protein stability, 
but the mechanism of stabilization can be more complex and difficult to elucidate than mutation.  
The carbohydrate entity or PEG molecule may increase protein stability through direct 
interactions with the protein or indirectly by shielding the protein from interaction with other 
protomers, often by occluding regions of hydrophobic surface area.15, 19, 127  Therefore, 
modulating the glycosylation pattern of proteins, such as Epo and interferon, may afford 
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increased stability, although the means by which this occurs is highly protein dependent.18-19, 128-
130  PEGylation provides an additional means of increasing physical stability due to the large size 
of the PEG molecule, which sterically hinders association among protein molecules.131-133  
1.3.1  Glycosylation  
Glycosylation, or the covalent attachment of carbohydrate moieties to the protein surface, 
can occur within a native protein sequence or non-native sites can be engineered into the native 
sequence.  The two main types of glycosylation are N- and O-glycosylation, which occur at Asn 
and Ser/Thr residues, respectively.  The presence of these residues alone does not always lead to 
glycosylation at this site.  N-glycosylation generally requires a consensus sequence,134 and the 
location of these residues within the three-dimensional structure of the protein can also dictate 
whether or not glycosylation occurs.  In Epo, full glycosylation is reliant upon preservation of 
the four-helix bundle, as mutants missing helical regions were not fully glycosylated.39  Also, the 
introduction of a bulky carbohydrate chain near the hydrophobic core would be detrimental in 
achieving the correct fold, which leads to lack of glycosylation near these regions.  
The addition of the glycan occurs during protein folding, suggesting it may contribute to 
folding in vivo with some glycosylation sites contributing more than others to the folding 
process.129, 135-141  Native O- and N-glycosylation in Epo has been shown to have minimal effects 
on protein structure and secretion.142, 143  Removal of the O-glycosylation site in Epo through 
substitution of Ser126 has no impact of the global conformation of the molecule.74  Even though 
elimination of all three N-glycosylation sites causes Epo to be produced mainly in the inclusion 
bodies in the E. coli system,18, 39, 144 the refolded molecule contains the same secondary and 
tertiary structure of the native protein,18, 144 suggesting that the structure of the protein is not 
modulated by the presence of the glycan moieties, but its stability may be.  The addition of non-
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native carbohydrate groups has also been shown to have minimal influence on the global 
structure of insulin145-146 and IFN-!-2b.130  On the other hand, native N-glycosylation of IFN-"-1 
assists in the formation of the stable three-dimensional structure.19  IFN-"-1b, which folds in the 
absence of the glycan, exhibits a Tm 7 °C lower than that of enzymatically deglycosylated IFN-"-
1a, which is folded in the presence of the glycan and then the glycan is removed.19  Removal of 
the N-glycan in IFN-"-1b also does not affect protein secondary structure once folding is 
achieved, 147 suggesting that the glycan assists in achieving, but not maintaining, the desired fold.  
The addition of glycan entities on the protein surface increases structural stability by 
limiting the structural mobility.129, 148  The size of the carbohydrate chains also contributes to 
folding stability by increasing the free energy associated with the unfolded state of the protein.13-
14  This increased folding stability afforded by glycosylation leads to measurable difference in 
thermal stability, as the glycosylated forms of IFN-",19 IL-5,128 Epo18, yeast external invertase, 
bovine serum fetuin, and glucoamylase129 all exhibit increased thermal stability in comparison to 
the deglycosylated forms.  The N-glycan motifs drastically influence Epo structure because their 
removal caused a decrease in molecular stability, whereas O-glycosylation does not contribute an 
appreciable amount to the stability of the molecule.149  Non-glycosylated Epo is also more 
susceptible to unfolding in the presence of denaturant, and it is less stable in acidic conditions.18, 
150  Acid-induced denaturation results in complete elimination of the tertiary structure of the 
mutant, but not of the glycosylated form, which suggests that the glycan moieties assist in the 
stabilization of the global structure of the protein at acidic pH.18  Glycan molecules can also 
modulate the thermal stability of IFN-!-2.  The IFN-!-2 variant containing four non-native 
glycans (Pro4Asn, Arg23Asn, Lys70Asn, Asp77Asn) exhibited a Tm approximately thirty 
degrees higher than the native O-glycosylated and E. coli generated non-glycosylated variant.130    
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The Tm values of the enzymatically deglycosylated 4N variant were the same as the native 
protein, confirming that it is the addition of the glycan moieties and not simply the amino acid 
mutagenesis that is responsible for the drastic increase in thermal stability, although a detailed 
description of the interaction between the protein surface and glycan has not yet been reported.  
The glycan within IgG1-Fc also directly interacts with the protein surface to stabilize protein 
conformation.  The outer and inner regions of the N-glycan at Asn297 within IgG1-Fc have the 
largest effect on protein conformation151 and are hypothesized to stabilize protein conformation 
through non-covalent interactions with nearby residues on the protein surface.16-17  Removal of 
the terminal N-acetylglucosamine resulted in the largest reduction in Tm (3.1 °C) with an 
additional decrease in Tm by 1.4 °C upon complete deglycosylation.152  In the solid-state 
structure, the loop containing the N-glycosylation site and the oligosaccharide are most perturbed 
by removal of the terminal N-acetylglucosamine or mannose sugar residues, suggesting an 
important role of these motifs in maintaining protein conformation.   
Even though glycosylation generally increases the folding stability, deglycosylation can 
also increase stability due to alterations in the protein conformation resulting in decreased 
hydrophobic surface area.153  The effect of the O-glycan on the thermal stability of IFN-!-2 is 
debated.  Johnston et al. reported Tm values of 65.7 °C and 63.8 °C for the non-glycosylated and 
O-glycosylated variants of IFN-!-2b,143 whereas Ceaglio et al. reported similar Tm values near 66 
°C for both forms.130  The O-glycosylation site is located within the flexible CD loop, and 
addition of GalNAc or Gal("1,3)GalNAc, which are two of the three major glycan moieties 
found in naturally produced IFN-!-2, decreases the conformational dynamics of the loop.154  
This suggests that flexibility of the loop is required for structural stability, as the rigidity 
imparted by the glycan molecule leads to decreased stability.  Because the observed difference in 
! 33 
thermal stability between the two variants is so small, additional experiments concerning the 
interactions between the glycan motifs and protein surface would prove useful in determining if 
the O-glycan is indeed destabilizing in IFN-!-2.  
In addition to contributing to protein folding, glycosylation may also increase the 
physical stability of the molecule.  At the high concentrations necessary for protein therapeutics, 
protein molecules may associate to form aggregates.155  Attachment of the glycan to the protein 
surface increases the solubility of the molecule due to the hydrophilic nature and steric effects of 
the carbohydrate,13 which leads to decreased aggregation propensity.134, 156-157  Introduction of 
non-native glycosylation sites increases the physical stability of IFN-!-2, as has been shown 
with other therapeutic proteins.18, 145-146, 150  The solubility of the monomeric form of insulin can 
also be increased through the chemical attachment of glycan molecules at the amino groups of 
the N- terminus of the A- or B-chain, and LysB29.  The tri-substituted molecule is the most 
monomeric derivative, but the stabilizing effects of glycan addition to the three locations are not 
completely additive.145-146  Shaking tests illustrate that the N-terminal A-chain modification 
increases the physical stability five-fold, N-terminal B-chain 20-fold and N-terminal B-chain-
LysB29 and trisubstituted molecule 30-fold.145-146  The N-terminal B-chain site and LysB29, are 
known to be dimer-forming surfaces (Figure 1.1),25-26, 32 and fibril formation has been shown to 
occur at the N-terminal portion of the B-strand,158 so glycan addition at this site in particular will 
lead to increased stability of the monomeric form by limiting self-association and fibril 
formation. 
The carbohydrate moiety may also increase the physical stability by shielding regions of 
hydrophobic surface area that are prone to interacting.  Severe precipitation of non-glycosylated 
Epo occurs after incubation at elevated temperatures and the helical content of the remaining 
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soluble portion is nonexistent; but, the glycosylated protein retains the native helical structure 
and remains soluble.18, 144  ANS fluorescence suggests that non-glycosylated Epo contains more 
solvent-exposed hydrophobic residues in comparison to the fully glycosylated form.18  Simply 
adding free N-glycans to non-glycosylated Epo results in decreased ANS fluorescence 
suggesting that the glycans do not need to be chemically attached to have the protective effect.150  
In Epo, the inner regions of the N-glycans were determined to be the part of the glycan moiety 
responsible for interacting with the protein surface.150  Removal of the galactose groups resulted 
in a decrease in denaturation stability and an increase in ANS florescence, suggesting that these 
groups are responsible for making the primary contacts with the hydrophobic surface area of 
Epo.  The glycan is also responsible for modulating the physical stability of IFN-"-1a.19, 60, 159  
Non-glycosylated IFN-"-1a exhibits a Tm 5 °C lower than glycosylated IFN-"-1a.19-20  The 
glycan forms hydrogen bonds with surface residues Gln23 and Asn86 of IFN-"-1a, further 
increasing the structural integrity of the molecule.15, 19, 61  It also shields a region of uncharged 
surface area so the observed increases in thermal stability could be due to either of these factors.  
In native IFN-!-2, glycosylation at this position is not required for maintaining physical stability, 
as this region contains charged residues that are unlikely to self-associate (Figure 1.7).53-54 In 
addition, the presence of the negatively charged sialic acid residues on the glycan may further 
decrease the self-associate propensity through electrostatic repulsion between neighboring 
molecules, as is observed with Epo.160-161  
The type of aggregate formed in the absence of the glycan also varies between IFN-"-1a 
and IFN-"-1b.  In IFN-"-1b, mainly soluble aggregates are formed that do not exhibit covalent 
properties,19 which suggests that the aggregation in this variant is primarily due to self-
association of non-charged regions within the protein.  On the other hand, the aggregates that 
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form in enzymatically deglycosylated IFN-"-1a are primarily composed of disulfide-linked 
complexes.19  Cys17Ser mutation results in increased physical stability so the decreased stability 
 
Figure 1.7  The glycan moiety within IFN-"-1 increases the structural and physical stability of the 
molecule.  The glycan forms stabilizing hydrogen bonds with residues Gln23 and Asn86 to maintain the 
structural integrity of the protein, and it also shields a surface-exposed region of uncharged residues.  IFN-
! does not require a glycan at this location because it contains charged residues in the analogous region, 
thus eliminating the region prone to self-association.  Reproduced with permission from Karpusas, M., 
Whitty, A., Runkel, L., Hochman, P. (1998) The structure of human interferon-!. Implications for 
activity. Cell. Mol. Life Sci. 54, 1203-1216, # 1998 Springer, New York.   
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upon deglycosylation of IFN-"-1a suggests that the glycan may modulate the reactivity of 
Cys17.  Partial unfolding may result in the ability of Cys17 to form intermolecular disulfide 
bonds due to increased exposure, which leads to decreased stability. 
1.3.2  PEGylation 
Covalent attachment of PEG to protein therapeutics has been shown to increase serum 
half-life and solubility, while also decreasing immunogenicity.8-12  PEGylation also affects the 
physical stability of proteins, and PEGylation of smaller protein therapeutics can be used to 
investigate the effect on a protein when site-specific chemical conjugation at different positions 
within the protein is accomplished.  Conjugation of a PEG molecule or drug entity usually occurs 
through the amino groups located on the N-terminus of the protein or surface-exposed lysine side 
chains but can also occur through non-native, engineered cysteine residues.  Conjugation through 
lysine or histidine residues is usually nonspecific and results in a highly heterogeneous product,2, 
162-165 whereas conjugation to non-native engineered cysteine residues allows for some degree of 
site specificity.5, 166  The conjugation site is mainly determined by properties of the protein, the 
number of possible conjugation sites within the protein, and the type of conjugation chemistry 
used. 
Site-specific PEGylation using native residues has been accomplished using knowledge 
of the reactivity of the potential conjugation sites in the protein of interest to develop the reaction 
conditions necessary for the desired modification site.  Insulin contains three potential 
PEGylation sites (N-terminus of the A-chain, LysB29, N-terminus of the B-chain), but site-
specific PEGylation at LysB29 is possible at high pH conditions (pH>9.5) because this amino 
group exhibits the highest reactivity under these reaction conditions.167  PEGylation at either site 
within insulin results in slight structural differences that depend on the conjugation site but not 
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the size of the PEG molecule,131-133, 168 suggesting that the residue modification and not size of 
conjugated entity causes structural perturbations.  The disubstituted  A-chain N-terminus/LysB29 
molecule exhibits a more intense !-helical feature due to the PEG molecule reducing the overall 
flexibility of native monomeric insulin.168  Substitution at LysB29 also causes restriction in the 
rotation of B-chain aromatic residues,131-132 suggesting that conjugation at LysB29 impacts the 
flexibility of the monomer more so than conjugation at the N-terminus of the A-chain.  On the 
other hand, PEGylation of IFN-!-2 at native lysine or histidine residues has minimal impacts on 
protein structure.  The attachment of a 12 kDa PEG molecule at His34 of IFN-!-2b does not 
cause substantial changes in the secondary or tertiary structure,164-165 and PEGylation at lysine 
residues is expected to have minimal effects on protein structure, as was the case with IFN-"-
1b.163  Although it allows for site-specificity, conjugation to engineered cysteine residues is 
performed less often because introduction of additional cysteine residues, particularly in the 
absence of a high-resolution structure, may result in glutathione adducts and product 
heterogeneity169-170 or have negative implications in protein folding.166  Selective reduction of 
disulfides within antibodies is used in ADC conjugation,3-4 but insertion of a much larger PEG 
molecule at this location would be highly detrimental to structural stability.  
Although PEGylation has been shown to minimally impact the structure of protein 
therapeutics, it does modulate the stability of the molecule.  PEGylation of Epo is hypothesized 
to occur either at His32 or His 94 and drastically increases its unfolding and aggregation thermal 
stability in comparison to the non-glycosylated form.144  A two-fold decrease in temperature-
induced aggregation was also observed with random lysine PEGylation of IFN-!-2b in 
comparison to the non-PEGylated counterpart.171  Because the global structure is not affected by 
addition of the PEG molecule, additional investigations are needed to determine if the PEG 
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molecule increases the thermal stability through modifications in local structure due to direct 
interactions with nearby residues.  On the other hand, the thermal unfolding of IFN-"-1b is not 
influenced by random PEGylation at surface exposed lysine residues, but the aggregation 
propensity of the molecule is decreased.163  This suggests that in the case of IFN-"-1b, the PEG 
molecule does not interact with the protein surface; rather it increases the stability of the 
molecule by sterically interfering with protein self-association.   
Because PEGylation can alter the exposed hydrophobic surface of the protein, it has been 
shown to increase protein stability in a similar manner as non-native glycosylation, although 
these effects are not as dramatic as the increases in PK activity provided by PEGylation.10  
PEGylation of insulin can increase the physical stability of the monomeric form by sterically 
hindering self-association at known contact points.  Conjugation at the N-terminus of the B-
chain, which is known to be a self-association contact point (Figure 1.1), increases the physical 
stability of monomeric insulin 36-40 fold in comparison to the 4-8 fold increase observed by 
conjugation at the LysB29 position.131-132  Addition of a PEG molecule at the PheB1 location 
prevents self-association by limiting the hydrophobic interaction site known to contribute to 
aggregation of monomeric insulin158, 172 and sterically restricting self-association.  The N-terminal 
portion of the A-chain must also contribute to fibril formation as disubstitution of the N-terminus 
of the A-chain and LysB29 resulted in a 8-fold increase in physical stability over 
monosubstitution of LysB29.133  As with glycosylation, the self-association propensity of the 
trisubstituted molecule was the lowest, suggesting monomer stability increases with increasing 
PEG substitution and size of the PEG molecule.133  PEGylation has also been shown to increase 
the physical stability of antibody fragments, allowing for the generation of high-concentration 
formulations > 200 mg/mL without protein aggregation.173  Because PEGylation allows for 
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increased physical stability with minimal structural implications, it is a very useful tool for 
generating protein therapeutics with the desired properties. 
1.4  CONCLUSION 
 The stability of protein therapeutics is modulated by many different factors including 
structural elements and surface properties, and investigating the effects of changing these factors 
is of critical importance, particularly for advancing beyond empirical evaluation to implement 
design of more stable therapeutics.  The generation of ADCs requires modulation in both the 
structure and surface of the antibody so the stability of the conjugate relative to the native 
molecule must be determined.  Because high-resolution data on antibody structure is limited, it is 
difficult to connect observed changes in molecule’s stability to the specific structural elements 
responsible for altering the stability.  As such, smaller protein therapeutics can serve as model 
systems for assessing the molecular mechanisms behind changes in stability.  In this review, the 
impact of modifying key elements responsible for stabilizing protein structure, such as hydrogen 
bonds, hydrophobic associations, and ionic interactions, within smaller protein therapeutics was 
analyzed and the trends observed were considered with respect to larger antibody systems.  
Mutations within smaller protein therapeutics are akin to chemical conjugation to antibodies 
because both modulate structural and surface properties, which directly impact stability.  Until a 
significant body of site-specific data are reported regarding the impact of conjugation on the 
structural stability of ADCs, the trends observed with mutation and modification of smaller 
protein therapeutics provide foundational principles for understanding structural stability, which 
can be applied when attempting to design site-specific conjugates and ADCs that exhibit the best 
possible stability profiles.  
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claMP TAG: A VERSATILE INLINE METAL-BINDING 
PLATFORM BASED ON THE METAL ABSTRACTION PEPTIDE 
 
2.1  INTRODUCTION 
Metals are extremely useful tools for clinical and biotechnology applications.  Metal-
based diagnostic imaging is common and its applications include molecular targeting to identify 
specific cell populations.1-2  Addition of metal-binding modalities to proteins has been 
accomplished primarily through chemical conjugation.3  Attaching a chelating agent requires use 
of a secondary chemistry, which leads to a heterogeneous mixture of products and requires 
optimization of the reaction conditions and additional purification steps to recover the desired 
product. 3-6  These reactions are inefficient, utilizing significant excesses of materials, and 
significantly increase the time needed to obtain a purified final product.  
Incorporation of a peptide-based metal-binding tag into a protein during expression to 
generate an inline carrier eliminates the need for subsequent modification, greatly simplifying 
the production of metal-based conjugates.  Inline lanthanide-binding peptide tags (LBTs) have 
been developed for binding to larger metal ions, such as gadolinium, demonstrating the validity 
of this principle.7-10  Lanthanide binding tags have found utility in a variety of applications, 
including imaging and biotechnology research.  They are large (~14-20 amino acids) because 
they must contain six residues positioned appropriately to enable binding lanthanide ions 
(Tb(III), Gd(III), Dy(III))7 using eight oxygen ligands.  The presence of a ninth exchangeable 
water ligand allows for the application of LBTs as MRI contrast agents.7, 9  In the laboratory, 
LBTs are used in luminescence energy transfer studies10 and for luminescence-based detection 
on gels.7  In addition, paramagnetic lanthanide ions are incorporated into LBTs for use as 
magnetic-field relaxation and alignment agents in NMR spectroscopy for evaluating protein 
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structure.8, 11  Lanthanide binding tags have found large utility as imaging agents, however, 
lanthanides are reported to induce significant adverse effects in some patient populations,12-14 
indicating additional approaches are needed.  Utilization of more biologically compatible 
transition metals is desirable, but the inability to achieve appropriate binding to these smaller 
metal ions by traditional chelators has hindered their use in the clinic.15-17  Nature typically 
accomplishes tight binding and control of transition metals using sophisticated protein scaffolds 
in which the metal is well protected from facile exchange.  These highly structured environments 
are absent in small peptides, which typically results in weaker binding and easier release of the 
metal to high affinity chelators, such as EDTA.  Thus a tag capable of sequestering smaller 
metals would enable new tools and provide opportunity to expand therapeutic and diagnostic 
applications.   
Our lab discovered the metal abstraction peptide (MAP) and its novel chemistry that 
binds transition metals and develops a uniquely structured product with compatible properties for 
use in clinical applications.18  The structure is extremely stable under basic conditions, resisting 
metal release and loss to high affinity chelators in competition experiments, but undergoes 
rearrangement upon acidification, permitting rapid exchange or release of the metal (manuscript 
in preparation).  MAP is composed of a three amino acid sequence (Asn-Cys-Cys; NCC), and the 
metal is coordinated by two thiolate ligands and two deprotonated amide nitrogens from the 
peptide backbone in a square planar organization when inserted inline with a protein sequence.19  
Because the sequence is composed of natural amino acids, it can be engineered as a tag into a 
genetic construct.  The desired protein product encodes the inline metal carrier, which we refer to 
as the claMP Tag.  In order to generate the specific metal-bound peptide structure having these 
unique properties, the claMP Tag must be reacted with a metal ion that is partially coordinated 
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by a chelator (Fig. 2.1), such as those used in immobilized metal affinity chromatography 
(IMAC), e.g. nitrilotriacetic acid (NTA).  The peptide abstracts the metal ion from the high-
affinity chelator; this reaction is extremely efficient and yields a highly stable, single product.19-21  
Here, epidermal growth factor (EGF) was used as a model system to demonstrate that the 
claMP sequence can be used effectively as a tag.  EGF contains six cysteine residues, which 
comprise three disulfide bonds, and its expression is known to require the assistance of disulfide 
modulating enzymes to fold correctly.22-25  Because the claMP Tag itself contains two cysteine 
residues, these additional thiols could complicate the folding process by increasing the number of 
possible folded states.  EGF was chosen because it exemplifies the extremes of protein systems 
to which the claMP Tag may be applied.  Production of EGF as a thioredoxin-fusion protein was 
performed to assess the ability to include the claMP Tag in a thiol- and disulfide-containing 
fusion protein.  Because the Ni-MAP complex has catalytic superoxide dismutase (SOD) 
activity,19 we confirmed that the SOD activity was retained when the Ni-claMP complex was 
incorporated inline with the EGF sequence and used this activity to quantitatively confirm 
formation of the desired product.  Here, the effects of the tag and its placement within EGF on 
Figure 2.1 Schematic that illustrates the unique method by which metal is inserted into the claMP Tag.  The 
claMP Tag is reacted with a chelated metal ion (i.e. Ni-NTA), which leads to metal insertion into the tag.  A metal 
ion with a 2+ charge, such as Ni(II), reacted with the net neutral claMP Tag sequence generates a single product 

















































expression, structure and native function of EGF are presented to demonstrate the compatibility 
and versatility of the claMP Tag for use as an inline metal carrier.  
2.2  MATERIALS AND METHODS 
2.2.1  Cloning and Construction of the Expression Plasmid 
Three DNA sequences were prepared to generate EGF variants: control EGF and two 
individually tagged variants containing the claMP Tag at either the N-terminus (GNCCG-EGF) 
or C-terminus (EGF-GNCCG) of the native sequence.  A plasmid containing human EGF was 
obtained (Origene, #RC210817), and the EGF sequence was amplified using PCR and subcloned 
into the pET-32Xa/LIC vector.  GNCCG was added to either the N-terminus or C-terminus of 
EGF and amplified using PCR for insertion into a LIC plasmid using the primers below (IDT). In 
each primer, the LIC sequence is underlined and the portion corresponding to EGF and the 
claMP Tag are not. 5’-GGTATTGAGGGTCGCGGAAACTGCTGCGGCAATAGTGACT 
CTGAATGTCCC-3’ (forward primer with tag on the N-terminus), 5’AGAGGAGAGTTAGA 
GCCGTCAGCGCAGTTCCCACCACTTCAG-3’ (reverse primer for N-terminally tagged 
construct), 5’-GGTATTGAGGGTCGCAATAGTGACTCTGAATGTCCCCTGTCCCACGAT 
GGG (forward primer for C-terminal tagged construct) and 5’-AGAGGAGAGTTAGAGCCG 
TCAGCCGCAGCAGTTTCCGCGCAGTTCCCACCACTTCAGGTC-3’ (reverse primer with 
tag on the C-terminus).  The amplification reactions were purified using the QIAquick PCR 
Purification Kit (Qiagen).  The fragments were inserted into the vector using the manufacturer’s 
protocol from the Xa/LIC cloning kit, according to the manufacturer’s instructions (Novagen). 
These plasmids contain a Thioredoxin tag, a His6 tag, thrombin cleavage site, S-tag, and Factor 
Xa site, which are all positioned on the N-terminal side of each EGF variant (Fig. 2.2).  The 
ligation product was transformed into the DH5! Escherichia coli cell strain using the standard 
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heat shock method, and the DNA was harvested after selection and growth on LB containing 100 
"g/mL ampicillin.  Plasmid DNA was purified using a miniprep kit (Qiagen), and the intended 
product was verified by DNA sequencing (UC Berkeley DNA Sequencing Facility).   
2.2.2  Protein Expression and Purification 
Expression and purification of the protein from these plasmids was completed in a similar 
manner as previously reported for EGF.26 Each plasmid was transformed into the Origami B 
(DE3) E. coli strain (Novagen) using the standard heat shock protocol.  Colonies were grown for 
~24 hours at 37 °C on LB agar plates with 100 "g/mL ampicillin, 30 "g/mL kanamycin, and 12.5 
"g/mL tetracycline.  To prepare 15N-labeled cultures, individual colonies were selected to 
inoculate 175 mL M9ZB media supplemented with 0.4% glucose, 1 mM MgSO4, and 100 "g/mL 
ampicillin.  These starter cultures were grown for 16 hours at 37 °C, 250 rpm.  Fifty milliliters of 
starter culture was used to inoculate 1 L minimal media containing minimal salts and trace 
minerals.27  To prepare non-labeled cultures, individual colonies were selected to inoculate 50 
mL LB media containing 100 "g/mL ampicillin. Again, starter cultures were grown for 16 hours 
at 37 °C, 250 rpm.  Twenty milliliters starter culture was used to inoculate 1 L LB supplemented 
with 100 "g/mL ampicillin.  Cultures of 15N-labeled media and non-labeled media were allowed 
to incubate at 200 rpm and 37 °C until an OD600 of 0.7 was met.  At this point, protein expression 
was induced through the addition of 1 mM isopropyl #-D-1-thiogalactopyranoside (IPTG).  The 
cultures were allowed to incubate for an additional 16 hours at 25 °C, 200 rpm, and then they 
were harvested by ultracentrifugation.  Cell pellets were stored at -80 °C until use.  
Each pellet (1 L of culture) was resuspended in 25 mL 50 mM Tris-Cl, 20 mM imidazole, 
pH 7.9 and lysed using a French Press at 21,000 psi.  The cellular debris was removed by 
centrifugation at 21,000 x g for 1 hour at 4 °C.  The supernatant, which contained the protein, 
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was filtered through a 0.45 "m filter and applied to a 5 mL Hi-Trap Chelating HP column 
charged with nickel (GE Lifesciences).  EGF constructs containing the claMP Tag were allowed 
to incubate on the column for one hour to facilitate metal transfer to the tag.  Cellular proteins 
were removed by washing the column with six column volumes (CV) of 50 mM Tris-Cl, 40 mM 
imidazole, 500 mM NaCl, pH 7.9.  The protein was eluted from the column using a linear 
gradient from 0-100% 20 mM sodium phosphate (NaPi), 500 mM NaCl, 500 mM imidazole, pH 
9.5 over 12 CV.  The thioredoxin tag was cleaved using 10 units thrombin (FisherScientific) per 
mg of protein at 16 °C for 9.5 hours, and the two cleavage fragments were separated on a 
Superdex75 column (GE Lifesciences).  The remaining tags were cleaved using 9 units Factor 
Xa (Novagen) per mg of protein at 25 °C for 16 hours, and the two cleavage fragments were 
separated on a Superdex75 column.  Samples were concentrated using an Amicon Ultra 3 kDa 
MWCO concentrator (Millipore) to a final concentration of approximately 0.15 mM.  The purity 
of the protein was confirmed with SDS-PAGE and size exclusion chromatography (TSKgel 
G3000SW, 7.8 mm x 30 cm, 5 "m particle size, Fisher Scientific) and the molecular weight was 
validated with ESI-MS.  Samples were quantified using a Bradford assay.     
2.2.3  SDS-PAGE Analysis 
Tris-tricine gels were prepared as reported.28  EGF constructs were separated using a 
discontinuous system consisting of a 4 % (v/v) stacking gel and a 18 % (v/v) resolving gel. The 
samples were prepared in non-reducing Laemmli buffer and heated for 10 minutes at 90 °C 
before being loaded onto the gel.  A prestained, dual-color molecular weight marker was used for 
reference (BioRad, #161-0374).  Gels were stained using Coomassie (R-250). 
Densitometry analysis was performed on Coomassie-stained tris-tricine gels using the 
Typhoon TRIO Variable Mode Imager (Amersham Biosciences).  Relative quantitation was 
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performed using the ImageQuantTL software (Amersham Biosciences).  The amount of claMP-
Tagged EGF was determined based upon the intensity observed for native EGF.       
2.2.4  Absorption Analysis 
 After purification, samples were diluted and analyzed using electronic absorption 
spectroscopy to confirm Ni(II) incorporation.  Samples were placed in a cuvette with a 1-cm path 
length and spectra were acquired from 200-800 nm using a Carey 100 Bio UV-visible 
spectrophotometer (Varian).   
2.2.5  HPLC Analysis 
Anion exchange chromatography (AEC) was performed on a 4 x 250 mm BioLC ProPac 
Wax10 column (Dionex).  The column was equilibrated with 20 mM Tris-Cl, 10 mM KCl, pH 
7.5 before injection of the sample.  A linear gradient from 0-100% 20 mM Tris-Cl, 500 mM KCl, 
pH 7.5 over 70 mL with a constant flow rate of 1 mL/min was used to elute the protein from the 
column and detected by absorbance at 220 nm.  The sample volume used for all injections was 
20 "L, and each sample was run in duplicate.  
2.2.6  1H-15N HSQC Analysis 
Two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) spectra were 
obtained at 25 °C using a 600 MHz Bruker Avance NMR spectrometer with a cryogenic, triple 
resonance probe.  15N-labeled protein was in prepared 50 mM KPi, 10 mM NaCl, pH 7.3, with 
6% D2O.  A Bradford assay was used to determine the concentration of the samples.  Data were 
obtained with 177 and 217 scans for EGF and EGF-Ni-claMP, respectively.  A different number 
of scans were used to account for variations in sample concentrations and achieve a similar 
signal to noise ratio for each 2D spectrum.  Analysis of the data was performed using NMRPipe29 
and the NMR assignment program Sparky.30 
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2.2.7  Xanthine/Xanthine Oxidase SOD Activity Assay 
This assay was performed as previously described.19, 31-32  Briefly, 600 µM cytochrome c 
from bovine heart and 300 µM xanthine were added to 50 mM potassium phosphate with 100 
µM EDTA, pH 7.8 to yield final concentrations of 10 µM cytochrome c and 50 µM xanthine.  
Enough xanthine oxidase was added to cause a change in absorbance at 550 nm of 0.02 to 0.04 
AU/min.  Several concentrations were analyzed to develop an IC50 curve.   
2.2.8  Cell Culture 
Human epidermoid carcinoma cells (A431, ATCC CRL-1555) were purchased from 
American Type Culture Collection (ATCC) and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin.  Cells 
were cultured in an incubator at a constant temperature of 37 °C and 5 % CO2.  
2.2.9  EGF Cell Viability Assay 
A431 cells were seeded in a 96-well clear bottom black plate at a density of 10,000 cells 
per well and incubated overnight in the growth conditions described above.  The following day, 
the media was replaced with media containing the test samples and controls.  Test samples were 
diluted into media at the appropriate concentrations and then transferred onto the cells.  Nine 
different concentrations were used, and each sample was run in triplicate.  The cells were 
incubated with EGF variants for 72 hours, when the control cells reached confluency.  Cell 
viability was measured using the CellTiter-Blue assay (Promega) following manufacturer’s 
protocol.  Briefly, the media was replaced with cell culture medium containing reagent and 
allowed to incubate for 30 minutes.  Following this incubation period, a microplate reader 
(SpectraMax GeminiXS) was used to determine the fluorescence intensity of the dye 
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(560ex/590em).  The fluorescence intensity was compared to control wells to determine percent 
viability. 
2.3  RESULTS 
2.3.1  claMP Tag Addition Does Not Impair EGF Expression 
Because native EGF contains three disulfide bonds, it was important to determine the 
extent to which addition of the two cysteine residues in the claMP Tag might affect protein 
expression or lead to non-native disulfide bond formation and misfolding in an E. coli system.  
Native EGF, like many disulfide-containing proteins, accumulates in inclusion bodies when 
expressed into the reducing cytosolic environment of E. coli 24, 33 and addition of the claMP Tag 
did not affect this outcome (unpublished data).  By expressing EGF in an engineered strain that 
contains a more oxidizing cytoplasmic environment, proper folding is achieved (Fig. 2.2).26, 34  
Using this approach, EGF and claMP-Tagged EGF variants were produced in the soluble 
fraction of the cell lysate. 
 SDS-PAGE was used to verify the claMP Tag did not adversely affect expression of 
claMP-Tagged EGF; all EGF variants showed excellent expression and reasonably similar 
expression levels (Fig. 2.3).  The molecular weight of each fusion protein was expected to be 
approximately 24 kDa.  As shown in Figure 2.3a, no band is present at this size in the pre-
induction samples (lanes 2, 4, and 6), but a band appears in the post-induction sample for each of 







Figure 2.2  Cartoon of pET-32 expression construct of recombinant claMP-Tagged EGF. 
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the various constructs (lanes 3, 5, and 7), confirming successful expression.  Native EGF was 
used as a standard to establish relative expression of the claMP-Tagged forms.  N-terminal and 
C-terminal placement led to a 14% and 29% decrease in EGF expression yield, respectively.  
Differences in expression among the variants were on the same order as batch-to-batch variation 
among replicates of the same protein.  Therefore, insertion of the claMP Tag into the protein 
sequence has a negligible effect on protein expression, as determined by densitometric analysis 
of whole cell lysates.  
2.3.2  claMP-Tagged EGF Is Soluble  
The EGF variants accumulated in the soluble fraction of the cell lysate, as determined by 
SDS-PAGE analysis of the supernatant and pellet from each sample following centrifugation of 
15 kDa 
10 kDa 




1 2 3 4 
b a 
Figure 2.3  SDS-PAGE analysis of claMP-Tagged EGF expression and final product.  Addition 
of claMP Tag to EGF did not significantly hinder expression or purification of desired product.  
Coomassie stained 18 % tris-tricine gels illustrating the expression of pET-32-EGF, pET-32-claMP-
EGF, and pET-32-EGF-claMP and final purified EGF products.  (a) (Lane 1) molecular weight 
standard, (lanes 2, 4, 6) E. coli lysate of pET-32-EGF, pET-32-claMP-EGF, and pET-32-EGF-claMP 
before IPTG induction, (lanes 3, 5, 7) E. coli lysate of pET-32-EGF, pET-32-claMP-EGF, pET-32-
EGF-claMP 16 hours after IPTG induction.  (b) (Lane 1) molecular weight standard, (lane 2) purified 
EGF-Ni-claMP, (lane 3) purified EGF, and (lane 4) purified Ni-claMP-EGF.   
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the lysate (data not shown).  Following individual processing and purification steps, the yield of 
each protein variant was determined (Table 2.1).  SDS-PAGE was performed to examine the 
purity and amount of protein present at each step, and the pure final product is shown in Figure 
2.3b.  Cleavage of the fusion tags from EGF-claMP worked as expected, completely cleaving the 
fusion protein and yielding the expected amount of each product.  During Factor Xa cleavage, a 
30% lower yield was observed with the N-terminally tagged construct in comparison to EGF-Ni-
claMP (Table 2.1).  The claMP Tag abuts the Factor Xa recognition sequence, and therefore, it is 
hypothesized that cleavage efficiency is reduced because the Ni-claMP complex kinks the 
protein conformation near the site, limiting 
access by the protease to the cleavage site.  
Sample purity of the final EGF proteins 
also was assessed using size exclusion 
chromatography (Fig. 2.4).  As a control, 
native EGF was examined, and it elutes at 
12 minutes.  EGF-Ni-claMP elutes earlier 
than EGF at 10 minutes, which is expected 































Figure 2.4  Size exclusion chromatogram of EGF and 
claMP-Tagged EGF.  Size-exclusion chromatography 
verifies that one main species is present in the sample.  
EGF-Ni-claMP elutes slightly earlier than EGF. 
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EGF Mass Before 









8.2 2.3 3.2 0.5 14% 
12 ± 3%  7.2 2.0 1.7 0.1 9% 
EGF-Ni- 
claMP 
6.9 1.9 2.3 1.1 45%  
 
 
43 ± 7% 
 15.1 4.2 4.8 1.6 34% 
 12 3.3 3.0 1.5 50% 
EGF 11.8 2.3 3.2 0.5 14%  
 
53 ± 7% 
 7.6 2.0 1.3 0.7 60% 
a The mass of EGF within the fusion protein was determined by taking into account the molecular weight of the 
fusion protein and EGF in the construct.   
b The mass of EGF within the fusion protein was determined by taking into account the molecular weight of the 
remaining portion of the fusion tags and EGF in the construct. 
c Percent yield was determined by comparing the final yield to the theoretical amount of EGF before the final 
cleavage step.  The second cleavage step was used to determine the percent yield. 
 
2.3.3  claMP-Tagged EGF Is Correctly Folded  
The three disulfide bonds present in EGF are the primary contributing factors to the 
protein structure.  As such, conservation of the native disulfide bonds is essential to preserve 
protein structure and maintain biological function.  Formation of the native disulfide bonds in 
EGF occurs through multiple iterations of incorrect cysteine pairs until the correct disulfide 
network is achieved,35 and addition of the claMP Tag introduces two additional non-native 
cysteine residues into EGF, which could interfere with the native disulfide network.  To validate 
that addition of the claMP Tag to EGF did not affect protein structure, two-dimensional 
heteronuclear NMR was used to compare the variants to native EGF (Fig. 2.5).26  A 1H-15N 
HSQC spectrum provides a fingerprint of the protein; each amide from the backbone generates 
one peak, which reflects the unique conformation of the corresponding residue within the 
structured protein.  1H-15N HSQC spectra obtained for EGF and EGF-Ni-claMP are highly 
similar and have specific, localized differences.  The spectra show that the native fold of the 
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protein is maintained in the presence of the claMP Tag, as the majority of the residues in both 
spectra overlay.  The disulfide network is also maintained; the chemical shift positions of the five 
assigned cysteine residues remain unperturbed.  The data show that the tertiary structure is not 
altered by the addition of the claMP Tag.  In the EGF-Ni-claMP spectrum, a few notable 
differences from native EGF are observed; residues near the C-terminus of the protein (K48, 
W49/50, L52, and R53) are shifted. There also are differences in peak intensity observed 









Figure 2.5  1H-15N HSQC spectrum of EGF and EGF-Ni-claMP.  Higher order protein 
structure is maintained in the presence of claMP Tag.  1H-15N HSQC spectra of EGF (blue) and 
EGF-Ni-claMP (red) at 0.1 mM and 0.08 mM, respectively.  Peaks from native EGF that 
decrease in intensity when the tag is present are labeled with their corresponding residues.  
Shifted peaks corresponding to C-terminal residues are circled.  New peaks 1, 2a, and 2b appear 
due to the addition of the claMP Tag.  Peak 1 corresponds to a glycine residue and Peaks 2a and 
2b correspond to the asparagine side chain amide.   
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changes in local environment, the presence of the metal-bound claMP Tag would be expected to 
influence the chemical shift of neighboring residues.  The chemical shift positions of EGF with 
and without the tag were compared and the differences mapped onto the structure of EGF to 
show the residues affected by the tag.  The structure reveals that the negatively charged Ni-
claMP module likely associates with a neighboring patch of positive charge (Fig. 2.6).   
 
   
In addition, three peaks emerge in the EGF-Ni-claMP spectrum, which may be due to the 
addition of residues composing the tag.  We expect Peak 1 corresponds to the amide backbone of 
one of the glycine residues because it appears in the glycine region.  The backbone of the 


















Figure 2.6  Illustration of the potential location of Ni-claMP within the EGF molecule.  (a) Schematic of 
EGF molecule; residues affected by addition of the claMP Tag on the C-terminus are shown in grey.  (b) 
Electrostatic surface map of EGF with the Ni-claMP complex added onto the C-terminus.  The negatively 
charged Ni-claMP complex is hypothesized to associate with the positively charged pocket shown in blue. 
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metal via these nitrogens, deprotonating them.  The other two residues do not generate 
observable peaks in the HSQC.  The asparagine side chain from the tag is visible in the 
spectrum, and it appears as a new pair of peaks with unique 1H values and the same 15N chemical 
shift (Peaks 2a, 2b).   
2.3.4  Ni(II) Is Selectively Inserted into claMP Tag in the Presence of EGF 
 For the initial analytical development, Ni(II) was used to occupy the claMP Tag, because 
this is a well understood system in our lab.19-21  Insertion of Ni(II) into the claMP Tag can be 
accomplished using Ni(II)-charged IMAC resin or via solution transfer using aqueous Ni-NTA,19-
21 both resulting in formation of the desired Ni-claMP complex.  The claMP-Tagged EGF was 
produced as a His-tagged fusion protein, which accomplished affinity purification and facilitated 
complete Ni(II) transfer into the claMP Tag during the purification process.  Use of IMAC resin 
for transfer has been shown to lead to full incorporation of Ni(II) into claMP-Tagged proteins as 
determined by ICP-OES and very efficiently limits nonspecific binding of Ni(II) to proteins 
(unpublished data).  EGF has previously been purified using Ni(II)-based affinity 
chromatography, and Ni(II) was not reported to nonspecifically bind to EGF.26  Control reactions 
performed with native protein in this study confirm this result. 
The Ni-claMP complex of the correct structure is rusty orange in color, allowing 
incorporation in the context of the protein to be confirmed with absorption spectroscopy, as 
established with the peptide system.21  In the EGF-Ni-claMP spectrum, there are broad features 
present in the visible region that reflect the structure of the unique metal complex, as seen in 
Figure 2.7a.  These features are absent from the control spectrum of native EGF, which confirms 
they are due to correct Ni-claMP formation, and not nonspecific binding of Ni(II) to EGF.  The 
Ni-claMP peptide module also exhibits additional features at longer wavelengths.  These features 
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are not apparent in the absorption spectrum of EGF-Ni-claMP shown in Figure 2.7a because a 
much higher protein concentration would be necessary, and this would cause the absorption from 
the protein to be off-scale.  
AEC also was used to verify that proper formation of the Ni-claMP complex was 
achieved.  Correct incorporation of Ni(II) into the claMP Tag creates a net charge of 2-.  Native 
and metal-free claMP-Tagged EGF each have an overall charge of 4-, but proper nickel insertion 
into claMP-Tagged EGF develops an overall charge of 6-.  This difference in charge results in 
unique AEC elution profiles for the two species.  As shown in Figure 2.7b, EGF elutes at 35 
minutes, whereas EGF-Ni-claMP elutes at 75 minutes.  The greater negative charge of EGF-Ni-
claMP causes it to bind more strongly to the cationic resin allowing AEC to be utilized to 
confirm metal binding and to separate the two distinct charge species. 
 As it has been shown that the Ni-claMP complex acts as a superoxide mimic,19 
verification of complex formation in the presence of EGF can be confirmed using a standard 
SOD activity assay.  The IC50 values for the Ni-MAP module and EGF-Ni-claMP are 35 ± 8 µM 











































Figure 2.7  Absorption spectra and AEX chromatogram of EGF and EGF-Ni-claMP.  Ni(II) is successfully 
incorporated into the claMP Tag in the presence of EGF.  (a) Absorption spectroscopy validates Ni(II) 
incorporation into the claMP Tag.  In comparison to EGF, EGF-Ni-claMP contains distinct features in the visible 
region, which confirm Ni(II) incorporation. (b) Anion exchange chromatography demonstrates the difference in net 
charge between EGF and EGF-Ni-claMP due to the addition of Ni-claMP. 
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and 44 ± 4 µM, respectively, which are comparable within experimental error for the 
xanthine/xanthine oxidase assay.  This confirms the Ni-claMP Tag specifically and efficiently 
forms the unique structure determined for the original Ni-MAP module and this module 
maintains comparable SOD-like activity in the context of the protein. 
2.3.5  EGF Remains Functional with Addition of claMP Tag 
In order to be used successfully as an 
inline metal carrier, the claMP Tag cannot be 
deleterious to the function of the protein.  A 
standard cell viability assay using the A431 cell 
strain was completed to assess the impact of the 
claMP Tag on EGF function.  This strain is 
known for its overexpression of the epidermal 
growth factor receptor (EGFR) on the cell 
surface.36  Overexpression of EGFR leads to the 
unexpected outcome of growth inhibition upon stimulation with EGF.36  The N- and C-terminus 
of EGF are not responsible for high-affinity binding to the receptor37 so placement of the claMP 
Tag on either terminus would not be expected to diminish EGF activity and indeed it does not.  
EGF or either claMP-Tagged variant of EGF elicits a similar cytostatic response (Fig. 2.8).  At 
nanomolar concentrations, addition of EGF or either Ni-claMP-EGF protein results in a 50% loss 




























Figure 2.8  EGF Activity Assay.  Addition of the 
claMP Tag to either the N- or C-terminus of EGF 
has little to no effect on the function of the protein.  
The decrease in cell viability of A431 cells caused 
by addition of EGF is comparable to that of both Ni-
claMP-EGF and EGF-Ni-claMP. 
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2.4  DISCUSSION 
Metal-binding agents enable a wide range of biotechnology, healthcare, and research 
applications.  Peptide tags and organic molecules capable of binding metal ions can be combined 
with the appropriate protein to allow for targeted delivery of metal ions for imaging and 
therapeutic applications and for use as analytical research tools.3, 8, 10, 38-40  Incorporation of a 
metal-binding tag into a protein can be accomplished using either chemical conjugation or inline 
addition.  Conjugating metal-binding organic molecules to proteins is typically performed using 
chemical means, primarily conjugation to lysine or cysteine residues using moiety specific 
chemistry.3-5, 41-42  Chemical conjugation using these approaches typically generates 
heterogeneous mixtures and the reactions often have poor yield of the desired product.5-6, 43-44  
Protein conjugates used in imaging and therapeutic applications must retain native protein 
structure and function in the presence of the peptide carrier containing the metal ion.  The claMP 
tag is similar in size to small chelating agents, but it bears the added advantage that placement 
within the protein can be controlled precisely.  These features of the metal claMP complex make 
it favorable for use in many applications.    
Typically, proteins are modified by attachment to lysine residues.  With chemical 
conjugation, protein function may be altered because the exact attachment site cannot be 
controlled,45 and lysine residues are often present in receptor recognition sites of many proteins, 
including antibodies.46-47  In addition, in vivo PK may be affected.48  For example, modification 
of the Fc region can alter binding to FcRn, resulting in changes in biodistribution, endosomal 
recycling, and PK.49  Incorporation of an inline metal-binding peptide eliminates the need for 
conjugation chemistry and allows for the formation of engineered site-selective conjugates 
designed to preserve function of the native protein and optimize performance characteristics.  
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The tripeptide claMP Tag can be easily inserted into the gene of interest using standard cloning 
methodologies.  Here, it is demonstrated that addition of the claMP Tag into the EGF sequence 
allows for the generation of an inline metal carrier that can be positioned to avoid disrupting the 
protein’s function.  
While chelators have been developed that bind transition metals, their properties are often 
incompatible with clinical use.  Tight binding chelators to copper have been developed, but those 
with sufficiently slow off rates for in vivo use require very high temperature and long incubation 
times to accomplish binding.  SarAr technology is an exception, which achieves tight binding 
under reasonable conditions for use with proteins,50 but this chelator is selective for and only 
used with copper.51  The claMP Tag is capable of binding a wide range of transition metals, 
including many species that are used to enable imaging and therapeutic applications, under 
conditions amenable to retention of higher order protein structure.  Cytotoxic metal ions, such as 
Pt or Pd, can be loaded into claMP and have potential to be used in targeted oncology 
applications (manuscripts in preparation).  Radioactive tracer metals, such as 99mTc, 55Co, 64/67Cu, 
or 212Pb also can be incorporated into the tag (manuscripts in preparation), and these isotopes 
have proven utility in diagnostic imaging.52-58  While not currently in wide usage, 57Ni could be 
inserted in the tag and monitored based on its positron or x-ray emission.59-60  Ni-claMP also 
allows for the generation of a catalytic antioxidant,19-21 which may be useful as a targeted anti-
inflammatory agent or biotechnology reagent for selective detection of tagged proteins. 
 In order to investigate the potential of using the claMP Tag as an inline metal carrier, its 
effects on the expression, structure, and function of a thiol- and disulfide-containing protein and 
metal insertion into the tag were analyzed.  The spectroscopic and chromatographic data verify 
that incorporation of Ni(II) into the claMP Tag is not affected when the tag is placed inline with 
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a protein sequence.  The overall structure of claMP-Tagged EGF is also maintained, as the 
chemical shift positions of the native cysteine residues remain unaltered.  In addition, native 
function is maintained with claMP Tag inclusion at either terminus.  The study described here 
demonstrates successful inline incorporation of the claMP Tag into a protein, illustrating this tag 
provides opportunity to expand the range of applications in which metals may be used in 
biotechnology and healthcare. 
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STABILITY ANALYSIS OF AN INLINE PEPTIDE-BASED CONJUGATE FOR METAL 
DELIVERY: NICKEL(II)-claMP TAG EPIDERMAL GROWTH FACTOR AS A 
MODEL SYSTEM 
 
3.1  INTRODUCTION 
 Coupling of chelators to proteins allows for the generation of conjugates that enable 
metal-based imaging or therapeutic applications.1-3  Generally this requires optimization of linker 
chemistry and additional purification steps to obtain the desired product.1, 4-6  Even though the 
conjugated entities are much smaller in size than the protein molecule, the impact of their 
addition may not be insignificant.  These alterations often affect pharmaceutical properties, 
including solubility, chemical and physical stability, and colloidal behavior of the protein.7  The 
magnitude and type of effect depends on the specific position modified and the structural 
attributes of the protein,8 as well as the properties of the linker and attached compound.   
The physical stability of proteins depends on the core structure, packing interactions and 
surface composition.  The surface properties that develop in the folded state affect solubility and 
colloidal stability, but they also determine solvent access to core structural elements that 
contribute to the overall three-dimensional fold and aggregation propensity of the molecule.9  As 
such, the composition of the molecule’s surface significantly impacts its stability, which is 
altered by conjugation.  This principle is apparent when comparing homologous proteins or 
mutants having the same three-dimensional fold because each variant can exhibit widely 
different stability profiles depending on their distinct surface properties.10-11  Charged residues 
located on the surface of structured proteins often increase the physical stability by protecting 
against thermal unfolding10-11 or by decreasing aggregation propensity due to charge-charge 
repulsion between protein molecules.12  Conjugation to surface-exposed lysine residues is 




product heterogeneity.13  Even though conjugates are successfully formed using this chemical 
method, altering the surface charge can affect the stability of the molecule7, 14 and also introduce 
unexpected complexity, as multiple charge states have been observed when modifying a single 
lysine, depending upon its position in the structure.15  To be able to control and/or better 
characterize stability, conjugation to native or engineered cysteine residues and non-natural 
amino acids has been pursued to increase site specificity.16  Modification of native cysteine 
residues in antibodies has been performed by reducing inter-strand disulfide bonds and 
conjugating at these positions.  Heterogeneity is decreased greatly compared to lysine-based 
approaches, but complexity remains and physical stability can be adversely affected.8, 17-18  
Introduction of additional cysteine residues permits site-specific attachment, and the THIOMAB 
approach has demonstrated success in identifying suitable positions within antibodies for this 
purpose.19  Site-specific attachment of any type permits detailed analysis of the structure and 
stability of the protein conjugate, allowing for selection of desirable attributes. 
The claMP Tag is based on the metal abstraction peptide (MAP) composed of the amino 
acid sequence Asn-Cys-Cys (NCC).20-22  It has been shown to bind Ni(II), forming a single 
specific metal-peptide complex structure having an overall charge of 2- 20 and unusual binding 
and release properties.23  Incorporation of the NCC module into longer peptide sequences has 
been shown to have no discernable effect on complex formation.22  Therefore, the claMP Tag can 
be biosynthetically encoded into a protein to generate a linker-less bioconjugate,24 which 
eliminates the need to chemically link to a chelating moiety.  The specific metal abstraction 
chemistry performed by NCC occurs with a variety of transition metal ions.23  The claMP Tag 




(unpublished data); thus, it has the potential to serve as a metal-binding agent for use in a variety 
of imaging and therapeutic applications.  
Our previous study demonstrated that the claMP Tag can be successfully incorporated at 
different positions within a thiol- and disulfide-containing fusion protein composed of 
thioredoxin and epidermal growth factor (EGF) without any negative effects on the expression 
yield, structure, or function of the tagged protein.24  Herein is presented the solution stability of 
this model system, the Ni(II)-claMP-EGF conjugate and the Ni-claMP Tag module in the 
context of the EGF system, to demonstrate the potential of the claMP Tag in serving as an inline 
metal carrier.  The inline Ni-conjugates were stored in aqueous solution using two different 
buffers, and UV-vis absorption spectroscopy, liquid chromatography, mass spectrometry, 
circular dichroism, and NMR were used to characterize stability and changes in the conjugate 
structure over a 24-week period.    
3.2  EXPERIMENTAL METHODS  
3.2.1  Protein Expression and Purification 
Wild-type and claMP Tag constructs were expressed and purified as previously 
described.24  Briefly, the DNA sequence was inserted into the pET-32Xa vector using a pET-
32Xa/LIC cloning kit (Novagen).  The plasmid was transformed into the Origami B (DE3) cell 
strain (Novagen) followed by expression in either Luria Broth or MMTM (for NMR samples).  
All of the samples for NMR analysis were grown on 15N-labeled ammonium chloride (Isotech) as 
the nitrogen source.  After expression, a 1 L pellet was resuspended, lysed using a French Press, 
and purified using a Hi-Trap Chelating HP column (GE Healthcare) charged with Ni(II).  
Cleavage with thrombin and Factor Xa (Novagen) were completed to obtain the final product.  




concentrated to approximately 0.2 mM.  EGF and EGF-Ni-claMP were each prepared in either 
50 mM Tris-Cl, 10 mM NaCl, pH 7.3 or 50 mM potassium phosphate (KPi), 10 mM NaCl, pH 
7.3 and stored at 4 °C.   
3.2.2  Absorption Analysis  
UV-vis spectroscopy was used to monitor Ni(II) incorporation into the claMP Tag.  
Samples were placed in a 1-cm path length cuvette.  Spectra were acquired from 200-800 nm 
using a Cary 100 Bio UV-visible spectrophotometer (Varian).   
3.2.3  Size Exclusion Chromatography (SEC) 
Size exclusion chromatography was used to assess the purity of the sample and determine 
if larger molecular weight species formed over time.  Analysis was performed using a 4.6 x 300 
mm Yarra SEC-2000, 3 µm pore size column (Phenomenex).  The column was equilibrated in 
“Buffer A” (20 mM Tris-Cl, 10 mM KCl, pH 7.5 before injection of the sample.  A constant flow 
rate of 0.35 mL/min “Buffer A” over 40 minutes was used to elute the protein from the column.  
UV absorption at 220 nm was used to monitor protein elution from the column.  The area of the 
peak at 8 minutes was used to quantify the amount of monomer at each incubation time point.  
3.2.4  Anion Exchange Chromatography (AEC) 
AEC was performed using a 4.6 x 250 mM BioLC ProPac WAX-10 column (Dionex).  
Before sample injection, the column was equilibrated using “Buffer A”.  Protein was eluted 
using a linear gradient from 0-100% “Buffer B” (“Buffer A” + 500 mM KCl) over 70 minutes.  
A constant flow rate of 1 mL/min was used, and UV absorption at 220 nm was used to monitor 
protein elution from the column.  The area of the main peak at 75 minutes was used to estimate 




for duplicate samples analyzed on the same day.  Because large run-to-run instrument variation 
was observed, the elution profile was used to establish trends and not for absolute quantitation.   
3.2.5  1H-15N HSQC NMR  
To examine the structural stability of the constructs using 2D NMR, EGF and EGF-Ni-
claMP were prepared in two buffer systems at pH 7.3, 50 mM Tris-Cl and 50 mM KPi, each 
containing 10 mM NaCl and 6% D2O.  The samples were concentrated to approximately 0.1 mM 
for analysis.  1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra were acquired 
on a 600 MHz Bruker Avance NMR spectrometer with a triple resonance cryoprobe.  The 
spectra for EGF-Ni-claMP were acquired with 120 and 217 scans for the samples prepared in 
Tris-Cl and KPi, respectively, with 2048 points in 1H and 128* increments in 15N.  The numbers 
of scans used were selected to account for slight variations in sample concentration and achieve a 
similar signal to noise ratio.  All spectra were obtained at 25 °C.  Spectra were obtained at 
multiple time intervals to evaluate time-dependent changes to protein structure.  NMRpipe25 and 
SPARKY26 were used to process the spectra and for data analysis. 
3.2.6  Static Light Scattering 
 Static light scatter (SLS) data was collected with a Photon Technology International 
(PTI) spectrafluorometer (Edison, NJ) equipped with a four-position sample holder and a Peltier 
temperature controller.  Samples were prepared at a protein concentration of 0.5 mg/mL in 50 
mM KPi, 10 mM NaCl, pH 7.3 and loaded into a 0.2 cm x 1 cm cuvette.  The intensity of 
scattered light was detected by a photomultiplier tube at an angle 90° to the arc lamp white light 
source.  The excitation wavelength was set at 295 nm, and the emission wavelength range was 
from 250 nm to 350 nm.  Spectra were collected every 2.5 °C from a temperature range of 5 to 




was measured as a function of temperature.  The background was subtracted from each data 
point based upon a sample containing only buffer with no protein present.  Two samples were 
analyzed for each variant. 
3.2.7  Circular Dichroism 
 Circular dichroism (CD) spectra were collected using ChirascanTM Plus CD 
Spectrophotometer (Applied Photophysics, Surrey, UK) equipped with a Peltier temperature 
controller.  Samples were prepared at a protein concentration of 0.035 mg/mL in 50 mM KPi, 10 
mM NaCl, pH 7.3 and loaded into a 0.1-cm path length cuvette.  Spectra were acquired every 2.5 
°C from 5 to 80 °C, with a one-minute equilibration at each temperature.  An averaging time of 
0.5 seconds/nm and a bandwidth of 1 nm were used.  The molar ellipticity at 200 nm was plotted 
as a function of temperature.  The background was subtracted from each data point based upon a 
sample containing only buffer with no protein present.  Two samples were analyzed for each 
variant.       
3.3  RESULTS AND DISCUSSION 
The emergence of bioconjugates in imaging and therapeutic applications has led to the 
need to develop assays suitable for investigating the stability of the entire conjugate, which 
encompasses the stability of the modified protein and the conjugated entity.  The conjugation 
approach can affect the analysis methods used to analyze the bioconjugate and monitor stability.  
Typically, lysine conjugation is used, but it can result in a large degree of product heterogeneity 
that complicates analysis,10, 13 and it also can lead to differences in stability among different 
preparations.  The claMP Tag is advantageous in that it does not require chemical conjugation 
because inline insertion of this tag within the protein sequence allows for the generation of a 




The claMP Tag has been shown not to adversely affect EGF expression, folding and 
function.24  Here, claMP-Tagged EGF was used as a model system to analyze the stability of the 
claMP Tag in the context of a protein system and determine how the claMP Tag modulates 
protein stability.  The tag rapidly becomes fully occupied in the presence of the metal transfer 
agent, efficiently yielding a highly stable single species in solution.20, 22, 24  Nonetheless, in the 
event of incomplete loading the metal-occupied claMP-Tagged protein is easily separated from 
any residual unreacted proteins using ion exchange chromatography because the correctly 
formed Ni(II) complex develops a 2- charge, differentiating it from the unoccupied form.  This 
approach efficiently generates a single, homogeneous conjugate species, permitting the stability 
of the resulting product to be well characterized. 
3.3.1  Stability of EGF and Ni-claMP Tag within the Conjugate  
The stability of the metal-bound claMP Tag is important to investigate in order to 
successfully implement the tag as an inline conjugate.  Most biologics and conjugates are stored 
as lyophilized formulations, but they must be stable in solution for 1-2 months to retain activity 
during manufacture and administration.  Accelerated stability studies of ADCs have 
demonstrated that linking drugs molecules to antibodies leads to formation of high molecular 
weight species (HMWS) and diminished structural stability.8, 17 Here, dimers or HMWS could 
result from either covalent crosslinking via disulfide bond formation or Ni-based oxidation or 
bridging via the metal upon liberation from the tag.  SEC was used to investigate formation of 
multimers over time.  In the initial chromatogram, EGF-Ni-claMP elutes as a fully monomeric 
species exhibited by one main peak at 7.5 minutes (Figure 3.1).  This is in contrast to native 
EGF, which elutes as two peaks at approximately 8.5 and 9.5 minutes.  The presence of two 




slightly higher buffer concentration (30 mM Tris, 15 mM KCl) yields a broad single peak at 9.0 
min (data not shown).  Because the behavior is reversible, these peaks likely represent two 
conformers.  The presence of only one peak in the claMP-Tagged EGF chromatogram suggests 
the protein’s structural flexibility may be restricted to a single conformation in the presence of 
the negatively charged tag, which is adjacent to a patch of basic residues.  At the 12-week time 
point, the EGF-Ni-claMP peak shape is slightly altered, gaining a shoulder peak centered at 8.4 
minutes, corresponding to a smaller molecular weight species or the emergence of a second 
conformer, as observed with EGF. These SEC data show no evidence of dimers or HMWS even 
at 24 weeks. Earlier eluting species indicative of protein crosslinking or aggregation are not 
present, implying the global conformation and the Cys residues within EGF-Ni-claMP are 
unaltered.  The presence of Ni(II) has been observed to cause oxidative crosslinking of 
proteins.27 As such, the SEC data further implies that nickel is not released readily from the 
claMP Tag because dimers and HMWS do not emerge. 
To investigate changes in the Ni-claMP complex, such as loss of metal or alteration of 
the ligands around the metal center, absorption spectroscopy and charge-based separation was 
Figure 3.1  Size exclusion chromatography assessment of monomeric content.  EGF-Ni-claMP 
prepared in either Tris-Cl (a) or KPi (b).  At the initial time point, only one species is present in 
both samples.  After three months, mostly monomeric protein remains with the emergence of a 




used.  The nickel(II) complex was used to perform this initial stability study because its 
absorption spectrum is rich in structural detail,22 and any chemical or structural transformation of 
the Ni-claMP complex would alter the features in the UV-vis spectrum and the unique 2- charge 
of the complex.  The UV-vis absorption data shows that EGF-Ni-claMP is stable over a 12-week 
period, as no decrease in peak height was observed for the protein feature and only 
approximately a 10% decrease observed for the Ni-claMP feature (Figure 3.2).  After 24 weeks, 
a decrease in intensity of the feature at 310 nm, which corresponds to the Ni-claMP complex, 
Figure 3.2  UV-vis spectroscopy confirms Ni(II) is incorporated into the claMP Tag   
Absorption spectra of samples prepared in both Tris-Cl (a) and KPi (b).  Ni(II) remains 
incorporated in the claMP Tag regardless of buffer system chosen, as the intensity of the feature 
at 310 nm remains constant over the 12-week period with Tris-Cl (c) and KPi (d).  At the 24-
week time point, the intensity of the feature at 310 nm decreases, suggesting alterations occur in 
the Ni-claMP complex.  The intensity of the feature at 280 nm remains constant, indicating the 





begins to emerge.  Because correct formation of the claMP complex introduces a change in 
charge of 2-, Ni-claMP-Tagged EGF exhibits a significantly different elution profile than EGF 
when separated on an anion exchange column. AEC was used to investigate the stability of Ni-
claMP by evaluating the elution profile of soluble claMP-Tagged EGF over time.  EGF elutes at 
approximately 35 minutes, whereas EGF-Ni-claMP elutes at 75 minutes.  Samples prepared in 
either 50 mM Tris-Cl, pH 7.3 or 50 mM KPi, pH 7.3, each containing 10 mM NaCl, exhibited 
the same chromatographic feature at the initial time point, confirming the conjugate has the same 
surface charge regardless of the buffer system in which it is prepared (Figure 3.3).  This supports 
the SEC data, confirming the buffer choice does not noticeably impact the behavior of the 
molecule.     
Like native EGF, the AEC peak area of EGF-Ni-claMP prepared in either buffer is 
constant through eight weeks within instrument variability (+/- 20%), indicating the protein 
remains intact and soluble.  Peak area for these preparations decreased below the variability 
threshold to approximately 25% and 35% at the 12-week time point for samples prepared in Tris-
Cl and KPi, respectively (Figure 3.3).  Multiple samples were analyzed, and peak areas acquired 
from different batches were observed to deviate substantially at the same time point.  A 15-35% 
decrease in peak area was observed at the 12-week time point depending on the sample analyzed.  
Because the AEC peak area values were extremely noisy, these data were not useful for absolute 
quantitation and instead were used solely to identify general trends and changes in the profile.  
EGF-Ni-claMP prepared in KPi exhibits a downward trend in peak area starting at the 12-week 
time point, while the sample prepared in Tris-Cl also decreases in peak area, although to a lesser 
extent.  There is also the emergence of an additional peak around 50 minutes in the AEC 




intensity at later time points.  Because earlier elution indicates a specie is less negatively charged 
than the conjugate, this data suggests a cleavage event, likely resulting in removal of the Ni-
claMP complex, and/or alterations in the protein structure near this region has occurred. 
3.3.2  Identification of Cleavage Fragment 
To further investigate the possible cleavage event and determine if it leads to removal of 
the Ni-claMP complex from EGF, mass spectrometry (MS) was performed.  MS analysis of the 
Figure 3.3  Trend analysis by anion exchange chromatography to assess retention of intact EGF-
Ni-claMP.  The initial chromatograms of the conjugate prepared in either Tris-Cl (a) or KPi (b) are very 
similar, indicating the buffer choice does not alter formation of conjugate.  In the sample prepared in 
KPi buffer, a peak emerges at 50 minutes, indicating formation of a species with a less negative charge.  
c) The area of the peak at 74 minutes was plotted to reflect the amount of intact EGF-Ni-claMP 
remaining.  At 12 weeks, the area of this peak decreases by 25% and 35% for the samples prepared in 
Tris-Cl and KPi, respectively.  At 24 weeks, the area of this peak in samples prepared in Tris-Cl and 
KPi decreases by approximately 40% and 70%, respectively.  d) The area of the peak at 35 minutes was 
plotted to reflect the amount of intact EGF in solution, and it remains constant over the 24-week time 





sample after 24 weeks reveals hydrolysis of the peptide backbone occurs following L52 and 
preceding R53, the C-terminal residue of the native EGF sequence.  This validates the SEC data, 
which shows emergence of a smaller molecular weight species.  It also aligns with the AEC 
results, which indicate the degradant is less negative than the conjugate but more negative than 
native EGF.  EGF without its terminal Arg and the Ni-claMP complex would exhibit a charge of 
5-, causing it to elute later than native EGF but earlier than EGF-Ni-claMP.  The MS data 
support hydrolytic cleavage of the peptide backbone.  Because of the large variability observed 
between different sample preparations in the rate at which this species emerges and that cleavage 
occurs between Leu52 and Arg53, we hypothesize the primary degradant observed is caused by a 
minor, undetectable protease contaminant.  Both chymotrypsin and pepsin have been shown to 
cleave on the C-terminal side of leucine,28 which is consistent with the location of cleavage in 
this EGF conjugate.  Our system undergoes a long lab phase before cleavage occurs, suggesting 
that the protease activity may be dependent on sufficient accumulation of free Ni(II).  Over time, 
Ni(II) may be released from the claMP Tag, which then catalyzes the proteolytic cleavage of the 
protein.  However, evidence of metal-induced hydrolysis has been reported to occur in the 
presence of various ions, including Ni(II).29  This is specific to the sequence SHHK and depends 
on the presence of one of two embedded His.  Complete cleavage occurs in a substantially 
shorter time frame, suggesting that it is not the same mechanism since our system undergoes a 
long lag period before degradation begins.  In addition, it is clear that despite the presence of 
molecular oxygen in the samples throughout the incubation, no evidence of oxidation (e.g. 
methionine sulfoxide) was detected in the MS data, indicating the presence of the Ni-claMP Tag 
complex does not lead to chemical incorporation of oxygen into the targeting protein even after 




The emergence of the cleaved 
fragment is accompanied by visible 
precipitation.  The absorption at 280 nm 
remains constant at 24 weeks, but the 
absorption of the Ni-claMP feature at 310 
nm decreases, suggesting selective 
precipitation of the Arg53-Ni-claMP 
fragment.  Analysis of the NMR peak 
intensities also confirms precipitation of 
neither EGF nor EGF-Ni-claMP occurs.  It 
was determined previously that the cysteine 
residues are unaltered by addition of the tag 
and as such these resonances can be used to 
quantify the total amount of soluble monomeric protein in the sample.  The peak heights of the 
cysteine residues in the HSQC spectra remain constant over the 24-week period, confirming the 
intact EGF-Ni-claMP and cleaved EGF components remain in solution.  The peak heights 
corresponding to Arg53 and Gly from the claMP Tag decrease in intensity over the 24-week 
time period, further indicating cleavage and precipitation of the Arg53-Ni-claMP Tag fragment 
likely occurs (Figure 3.4).  Because the net charge of the Arg53-Ni-claMP fragment is 1-, 
presuming no other alterations, its aqueous solubility may be limited, particularly in the presence 
of the highly soluble, negatively charged protein, as might be predicted based on general 
principles and other peptides.11  
Figure 3.4  Plot of NMR peak heights.  The peak 
height corresponding to Cys residues confirms the 
protein structure is maintained and no loss of 
protein from solution occurs.  The peak heights 
corresponding to the Gly from the claMP tag and C-
terminal residues from EGF (L52, R53) decrease, 




The likelihood of this cleavage event occurring with a claMP-Tagged bioconjugate can 
be reduced by various standard measures, including frozen storage, lyophilization, and 
improving purification procedures to better eliminate proteolytic contaminants derived from the 
host, in this case E. coli.  In this study, a simple two-step purification was used, and no 
precautions were taken to inhibit proteases, chelate residual or released metal, or eliminaate 
oxygen and light exposure during storage. Follow-up studies to examine each parameter 
individually are being pursued to characterize their influence on conjugate stability.  In the 
construct examined here, a glycine spacer was included between EGF and the tag.  Examination 
of a matrix of synthetic peptides and tagged protein variants has shown the spacer is unnecessary 
for metal complex formation (unpublished data), indicating the spacer may be removed or 
substituted.  As such, if a spacer is desired, residues less prone to rapid cleavage than Gly can be 
utilized to reduce potential proteolysis.  Optimization of these external factors will allow for the 
formation of highly stable claMP-Tagged bioconjugates.  The basal conditions analyzed provide  
a good starting point for identifying stable formulation conditions, which is an important 
consideration in the development of bioconjugates utilizing the claMP Tag technology.  
3.3.3  Impact of the claMP Tag on the Structural Stability of EGF 
Because SEC showed the EGF proteins remained entirely monomeric and soluble at 24 
weeks, 2D heteronuclear NMR was used to more closely investigate the local structural stability 
of claMP-Tagged EGF.  It has previously been shown that addition of the thiol-containing 
sequence to the C-terminus of EGF does not negatively impact native disulfide bond formation 
or the higher order structure of the molecule.24  Here, the initial 1H-15N HSQC spectra of EGF-
Ni-claMP prepared in each buffer overlapped nicely, confirming the tertiary structure of EGF-




At the 12-week time point, additional peaks emerge near the initial resonance positions 
corresponding to the backbone amides from C-terminal residues W49, W50, E51 and L52.  The 
indole NH from the side chains of W49 and W50 begin to split from one overlapped peak into 
two.  These limited site-specific changes become more distinct at the 24-week time point, yet the 
global structure and disulfide network of the protein remain the same (Figure 3.6).  




N HSQC spectra of EGF-Ni-claMP in two buffer systems.  It confirms that buffer 
selection has no effect on the structure of EGF-Ni-claMP, as the peaks of the samples prepared in Tris-Cl 





Altering the surface properties of the molecule through claMP Tag addition did not 
significantly affect the structure or stability of EGF.  Thermal titration of EGF and EGF-Ni-
claMP were performed to determine the effect of adding the tag on the unfolding and 
aggregation of the protein.  The unusual fold of EGF produces a CD spectrum with atypical 
features.  The CD features of Ni-claMP overlap extensively with EGF above 220 nm and are 
opposite in sign, leading to the absence of an informative signal in this portion of the spectrum.  
As such, unfolding of EGF was monitored at 200 nm to detect changes in random coil. With and 
without the tag, EGF behaved identically (Figure 3.7).  The onset temperature for unfolding  
Figure 3.6  1H-15N HSQC spectra of aged EGF-Ni-claMP.  EGF-Ni-claMP spectra over a 24-week 
period with T=0 (green), T=12 weeks (blue), and T=24 weeks (red) shown.  The tertiary structure of the 





(Tm,onset) is indicative of the physical instability of the conjugate, as reported for ADCs.8  As such, 
the fact that the Tm,onset values of claMP-Tagged EGF and native EGF are indistinguishable, 
indicates that incorporation of the claMP Tag is innocuous.  Visible precipitation was not 
observed and unfolding was reversible for both species.  SLS was used to monitor formation of 
aggregates as a function of temperature, but no scattering could be detected for either protein up 
to the maximum temperature of 80 °C.  Because native EGF is highly negatively charged, it is 
not unexpected that making it more negative by addition of the Ni-claMP complex does not 
diminish stability.  Charge repulsion and retention of the disulfide bonds likely protects EGF 
from aggregation.  In the context of this system, alterations in surface charge due to claMP Tag 
addition were shown to have minimal effects on protein stability, which is promising for 
application of this tag in biotechnology applications.  Additional studies are ongoing to evaluate 
the effects on stability of incorporating the claMP Tag into a diverse set of proteins that vary in 
isoelectric point, size, charge, and architecture. 
 
Figure 3.7  CD Thermal Analysis of EGF Variants.  a)  Initial CD spectra of EGF variants taken at 5 
°C.  b) Plot of CD intensity at 200 nm of EGF and EGF-Ni-claMP as a function of temperature.  The 
tagged and non-tagged variants exhibited similar changes in random coil, confirming that the claMP Tag 






3.4  CONCLUSION 
In this study, the Ni(II)-claMP Tag complex was shown to retain metal binding and not 
negatively alter the higher order structural stability of the protein molecule to which it is 
attached.  Although cleavage of the Arg53-Ni-claMP fragment occurs, this is likely due to 
protease contamination, which can be mitigated by increasing sample and/or reagent purity as 
well as storing it frozen and/or dried.  Therefore, this stability analysis of the EGF-Ni-claMP 
conjugate confirms that the claMP Tag module is structurally and chemically stable and does not 
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DECOUPLING PROTEIN PURIFICATION AND METAL INSERTION AND 
QUANTIFYING RETENTION OF NI(II) BY claMP TAG IN PRESENCE OF HIGH 
AFFINITY CHELATOR: ANALYSIS OF MALTOSE-BINDING PROTEIN (MBP) 
VARIANTS 
 
4.1  INTRODUCTION 
 Incorporation of metal-binding modalities within a protein sequence allows for the 
generation of a bioconjugate capable of achieving targeted delivery of metal ions for use in 
imaging and therapeutic applications.  Most metal-binding modalities are small, organic 
chelators that require conjugation to the protein surface,1-5 which is typically done after complete 
purification of the protein.  Inline metal-binding tags are engineered into the gene of the desired 
protein to generate “linker-less” conjugates that do not require further chemical modification.6-7  
Inline tags do introduce additional complexities because they are attached to the protein before 
the protein is fully purified.  Purification procedures are time-consuming, which provides the 
opportunity for undesirable reactivity of the metal-binding tag during this process.  Therefore, 
when using peptide-based tags, the point of greatest metal insertion efficiency during the 
purification process must be determined to ensure that the highest yield of the desired product is 
achieved.  The effects of tag placement on the metal insertion efficiency must also be considered, 
as the fold of the protein could alter tag accessibility for metal insertion.  Chemical conjugation 
occurs when the protein is fully folded so surface accessible residues are the most common sites 
of conjugation, and the specific position of attachment cannot be controlled entirely,8-10 although 
methods of site-specific conjugation are being developed.11  Peptide tags may be engineered at 
any position within the protein sequence but are best positioned in places where no deleterious 
effects on the structure or stability occur.  The fold of the protein near the peptide tag can alter 
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metal insertion efficiency by limiting accessibility of the peptide tag if it is folded into the 
protein structure so the optimal site of tag placement must be determined.     
 Here, we present how metal insertion efficiency into the claMP Tag is altered by point of 
metal insertion during the purification process and placement of the claMP tag within the 
protein.  The claMP Tag is a novel metal-binding tripeptide based upon the metal abstraction 
peptide (MAP) sequence Asn-Cys-Cys (NCC) that is capable of being inserted inline within a 
protein sequence.  The tag has been extensively investigated in terms of its Ni(II) binding 
potential and generation of Ni-NCC produces an overall charge of 2- for the complex.12-14  This 
tag also has the ability to bind a variety of transition metal ions other than Ni(II) including 
cytotoxic metals, such as Pt and Pd, and radioisotopes, such as 99mTc, 64/67Cu, and 60Co,15 making 
it amenable to use as a tag in imaging and therapeutic applications.  Incorporation of the 
tripeptide into longer peptide sequences does not negatively impact metal binding,13 allowing for 
use of the claMP Tag as a “linker-less” conjugate.6  Because the claMP Tag contains two 
cysteine residues, the effects of these free thiols on the purification process must be assessed in 
order to successfully apply the claMP Tag as an inline metal-binding module.  Purification of 
proteins is very time-consuming, which may lead to undesirable reactivity of free thiols and 
elimination of a metal-coordination site.  To determine if this occurs within the claMP Tag, we 
evaluated the metal insertion efficiency when metal is introduced immediately after cellular lysis 
prior to purification or alternatively after purification is complete.   
Maltose-binding protein (MBP) was chosen for these analyses because it allows for 
separation of the metal insertion and purification steps.  Clean decoupling of these steps is not 
possible with His-tagged proteins because the polyhisitidine sequence also is capable of binding 
metal making it more difficult to selectively identify binding to the two tags.  The MBP-based 
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system permits analysis of different approaches to incorporate metal and the point of highest 
metal insertion efficiency during the purification process.  Antibodies are purified most often 
based on their high Protein A/G affinity,16-18 which, like MBP, does not involve use of metal.19-21  
The MBP system provided a more accessible approach for evaluating the importance of the 
timing of metal insertion into the claMP tag in order to better understand application of the 
claMP Tag technology to antibody systems, which are the primary scaffolds used for generating 
targeted therapeutic and diagnostic agents.2, 9, 11, 22-24 
In order to ascertain the usefulness of the claMP Tag as a metal-binding platform, the effects 
of the tag on different types of protein systems must be established.  The claMP Tag has been 
previously been shown to have no discernable affect on the expression, structure, or stability of 
the disulfide-containing protein epidermal growth factor (EGF).6, 25  Because this tag would need 
to be used with much larger proteins than the 53 amino acid protein EGF for successful use as a 
bioconjugate, insertion of the claMP Tag within the MBP sequence was used to assesses its 
affects on a larger protein with different structural properties.  MBP is a 40 kDa single-domain 
protein, which has a more typical structure26 and exhibits a greater negative charge than EGF.  
EGF is highly cross-bridged by disulfide bonds and contains few secondary structural elements, 
whereas MBP has an extensive amount of !-helical character defining its overall fold and no 
disulfide bonds.26  The claMP Tag was added to either the N- or C-terminus of MBP to 
determine if the site of tag addition would differentially modulate protein properties based on the 
structure of the region to which it is added.   
The success of metal-based bioconjugates is also highly dependent on their ability to retain 
metal binding in the presence of very high affinity chelators, such as EDTA.  It has been 
observed with peptide models that the claMP Tag retains metal in the presence of competitive 
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species, but this had not been quantitatively determined for the tag within a protein system.  
Here, we investigate the effect of excess EDTA on retention of Ni(II) by the claMP complex 
within claMP-Tagged MBP.  
4.2  MATERIALS AND METHODS 
4.2.1  Cloning and Construction of the Expression Plasmid 
Four different DNA sequences were prepared to generate MBP variants: control MBP 
and three individually tagged variants containing the claMP Tag at either the N-terminus (NCC-
MBP, GNCCG-MBP) or C-terminus (MBP-GNCCG) of the protein sequence.  A plasmid 
containing the MBP sequence from the MBP fusion protein system was obtained (NEB, 
#N8108S), and the MBP sequence was amplified using PCR and subcloned into the pET-22b(+) 
vector.  Custom primers (IDT) were used to generate N-terminal (NCC-MBP, GNCCG-MBP) 
and C-terminal variants (MBP-GNCCG) and amplified using PCR for insertion into pET-22b(+) 
vector using the NdeI and BamHI restrictions sites.  In each primer, the restriction site sequence 
is bold, the portion corresponding to the claMP Tag is italicized, and the remaining portion 
corresponds to MBP.  The primers used are as follows: 5’-! GGGAAT 
TCCATATGAACTGCTGCAAAATCGAAGAAGGTAAACTGGTAATCTGG -3’ (forward 
primer with NCC on the N-terminus), 5’-GGGAATTCCATATGGGAAACTGCTGCGGC 
AAAATCGAAGAAGGTAAACTGG-3’ (forward primer with GNCCG on the N-terminus), 5’-
CGCGGATCCTCAAGTCTGCGCGTCTTTCAGGGCTTCATCG-3’ (reverse primer for N-
terminally tagged variants), 5’-GGGAATTCCATATGAAAATCGAAGAAGGTAAACTGGT 
AATCTGGATTAACGGCG-3’ (forward primer for C-terminally tagged variants), and 5’-
CGCGGATCCTCAGCCGCAGCAGTTTCCAGTCTGCGCGTCTTTCAGGGC-3’ (reverse 
primer with GNCCG on the C-terminus).   
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 The amplification reactions were purified using the QIAquick PCR Purification Kit 
(Qiagen).  The inserts and pET-22b(+) vector were digested using the NdeI and BamHIHF 
restriction enzymes for two hours at 37 °C.  A four-fold molar excess of digested insert was 
added to digested vector and incubated with T4 ligase at 16 °C for 16 hours.  The ligation 
product was transformed into the DH5! Escherichia coli (E. coli) cell strain using the standard 
heat shock method, and the DNA was harvested after selection and growth on LB medium 
containing 100 "g/mL ampicillin (AMP100).  Plasmid DNA was purified using a miniprep kit 
(Qiagen), and the intended product was verified by DNA sequencing (UC Berkeley DNA 
Sequencing Facility).   
4.2.2  Protein Expression  
Each plasmid was transformed into the BL21 (DE3) E. coli strain (Novagen) using the 
standard heat shock protocol and transformants selected on LB agar plates with AMP100. 
Individual colonies were cultured in LB/AMP100 at 37 °C and 250 rpm for 16 hours and then 6 
mL was transferred to 1 L in LB/AMP100 plus 0.2% glucose.  Protein expression was induced at 
OD600 of 0.7 by the addition of 1 mM isopropyl #-D-1-thiogalactopyranoside (IPTG).  Cells were 
harvested after 4 hours using centrifugation, and pellets were stored at -80 °C until use.  
To quantitatively determine the expression levels of the MBP variants, a sample was 
taken from each culture after the four-hour incubation.  The total cell mass collected for each 
variant was determined based on the sample volume collected and OD600 value (volume 
sample=(0.8*200)/OD600 at 4 hours).  The sample was centrifuged and the supernatant removed 
to yield only the cell pellet.  The pellet was solubilized in 8 M urea, followed by an equivalent 
amount of SDS loading buffer.      
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4.2.3  SDS-PAGE Analysis 
MBP variants were separated using a discontinuous system consisting of a 5% (v/v) 
stacking gel and a 12% (v/v) resolving gel. The samples were prepared in non-reducing or 
reducing SDS loading buffer and heated for 10 minutes at 90 °C before being loaded onto the 
gel.  A prestained, dual-color molecular weight marker was used for reference (BioRad, #161-
0374).  Gels were stained using Coomassie (R-250) to visualize protein.   
Densitometry analysis was performed on Coomassie-stained SDS-PAGE gels using the 
Typhoon TRIO Variable Mode Imager (Amersham Biosciences).  Relative quantitation was 
performed using the ImageQuantTL software (Amersham Biosciences).  
4.2.4  Protein Purification  
Each pellet (1 L of culture) was resuspended in 25 mL Lysis Buffer (50 mM Tris-Cl, 200 
mM NaCl, pH 8.4 containing 2.5 mM "-mercaptoethanol ("ME)) and lysed using a French Press 
at 21,000 psi.  A control sample was also prepared in the absence of "ME in the lysis buffer to 
verify that its addition does not alter metal incorporation.  The cellular debris was removed by 
centrifugation at 21,000 rcf for 1 hour at 4 °C.  The supernatant, which contained the protein, 
was filtered through a 1.2 "m followed by a 0.45 "m filter. Metal insertion before and after 
amylose resin purification was tested, using a protein concentration of approximately 0.1 mM 
during each metal-incubation step.  For insertion of metal before amylose resin purification, the 
filtered supernatant was added to 15 mL IMAC Sepharose 6 Fast Flow resin charged with nickel 
(GE Lifesciences) and allowed to incubate for one hour to facilitate metal transfer to the claMP 
Tag.  Because the protein lacks the polyhisitidine tag, it is not expected to bind to the IMAC 
resin.  As such, the flowthrough from the column was collected, washed with an additional three 
column volumes (CV) of Loading Buffer (50 mM Tris, 200 mM NaCl pH 8.0) to completely 
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elute the protein from the column.  The protein fraction (75 mL) was diluted with an additional 
25 mL Loading Buffer and passed over a 15/100 flex column containing 15 mL amylose high 
flow resin (NEB), using a peristaltic pump.  After loading the protein, the amylose resin was 
washed with 2 CV Loading Buffer.  The protein was eluted from the amylose resin using 
Loading Buffer containing 10 mM maltose.   
The effects of inserting metal after complete purification, following elution from the 
amylose resin, also were tested.  The filtered lysate was diluted five-fold, added to the amylose 
resin, washed, and eluted as above.  The eluted protein was then incubated with 15 mL IMAC 
Sepharose 6 Fast Flow resin charged with nickel for one hour and eluted as above.  The 
efficiency of metal insertion using either IMAC Sepharose 6 Fast Flow resin charged with nickel 
or the preformed, soluble complex of nickel incorporated nitrilotriacetic acid (Ni-NTA) was 
investigated.  During these studies, the metal was incubated either with Ni-IMAC resin or 1:1 
molar ratio of a solution of Ni-NTA for one hour before purification with the amylose resin.  
Because the claMP Tag binds one Ni(II) per claMP sequence, a 1:1 Ni(II): claMP-Tagged 
protein ratio was chosen for the Ni-NTA incubation.  Peptide studies have shown that incubation 
with higher ratios of Ni(II):claMP sequence is unnecessary because full claMP Tag saturation is 
achieved at a 1:1 ratio.    
Following metal insertion and amylose purification, the protein was purified further using 
a self-packed Superdex75 C16/100 column (GE Lifesciences).  Samples were concentrated using 
an Amicon Ultra 30 kDa MWCO concentrator (Millipore) to a final concentration of 
approximately 0.75 mM.  Samples were quantified using a Bradford assay.  The purity of the 
protein was confirmed with SDS-PAGE and size exclusion chromatography, and the molecular 
weight was confirmed using ESI-MS. 
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4.2.5  Absorption Analysis 
 After purification, samples were analyzed using UV-vis spectroscopy to confirm Ni(II) 
incorporation.  Samples were placed in a cuvette with a 1-cm path length and spectra were 
acquired from 200-800 nm using a Cary 100 Bio UV-visible spectrophotometer (Varian).  
4.2.6  HPLC Analysis 
Anion exchange chromatography (AEC) was performed on a 4 x 250 mm BioLC ProPac 
Wax10 column (Dionex).  The column was equilibrated in 30 mL “Buffer A” (20 mM Tris-Cl, 
10 mM KCl, pH 7.5) before injection of the sample.  A linear gradient from 0-100% “Buffer B” 
(Buffer A + 500 mM KCl) over 70 mL with a constant flow rate of 1 mL/min was used, and UV 
absorption at 220 nm was used to monitor protein elution from the column.   
4.2.7  Determination of Ni(II) Insertion Efficiency Using SEC 
 The two peaks present in the SEC chromatogram were determined to correspond to 
Ni(II)-incorporated and Ni(II)-free versions of claMP-Tagged MBP using AEC.  To determine 
the insertion efficiency (%), the area of the peak corresponding to Ni(II)-incorporated claMP-
Tagged MBP was divided by the total area of the two peaks in the chromatogram and multiplied 
by 100%. 
4.2.8  Circular Dichroism 
 Circular dichroism (CD) spectra were collected using ChirascanTM Plus CD 
Spectrophotometer (Applied Photophysics, Surrey, UK) equipped with a Peltier temperature 
controller.  Samples were prepared at a protein concentration of 0.5 mg/mL in 50 mM KPi, pH 
7.3, with 10 mM KCl, 120 mM KCl, or 140 mM KCl, which corresponds to an ionic strength of 
142 mM, 252 mM, and 272 mM, respectively, and loaded into a 0.1-cm path length cuvette.  
Spectra were acquired every 2.5 °C from 5 to 85 °C, with a one-minute equilibration at each 
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temperature.  An averaging time of 0.5 seconds/nm and a bandwidth of 1 nm were used.  The 
molar ellipticity at 222 nm was plotted as a function of temperature.  The background was 
subtracted from each data point based upon a sample containing only buffer with no protein 
present.  Two samples were analyzed for each variant.  The Tm was determined by applying a 
sigmoidal curve that best fit the data between 20 °C and 85 °C.  The thermal unfolding curve of 
MBP-Ni-claMP contained two transitions so two different Tm values were determined for each 
by applying a sigmoidal curve that best fit the data between 20 °C and 62.5 °C and between 57.5 
°C and 85.0 °C.  The R2 values of these curves were all greater than 0.985.   
4.2.9  EDTA Competition Analysis 
 EDTA was added to the samples to obtain a final concentration of 10 and 100 mM 
EDTA, which equates to a 10- and 100-fold molar excess over Ni-claMP Tag protein in the 
competition reaction.  The EDTA-spiked samples were allowed to incubate at 4 °C and aliquots 
were pulled at the 2 hour, 24 hour, and one week time points to be analyzed using UV-vis 
spectroscopy and HPLC as described above.  Control samples without EDTA were also analyzed 
to confirm changes in intensity were due to EDTA addition and not protein degradation.  All 
samples were tested in duplicate.   
4.3  RESULTS AND DISCUSSION 
4.3.1  Addition of claMP Tag Does Not Hinder MBP Expression 
It has previously been shown that claMP Tag addition does not negatively impact the 
expression of a thiol- and disulfide-containing fusion protein composed of thioredoxin and 
epidermal growth factor (EGF).6  Here, an unrelated protein having a different composition, 
architecture, and size was examined to further confirm claMP Tag placement into recombinant 
proteins provides a robust, flexible platform.  The molecular weight of the final Ni-claMP 
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Tagged-MBP products is approximately 40 kDa, which is six times the size of the previously 
characterized EGF system.  Regardless of tag location or sequence (GNCCG versus NCC), 
addition of the claMP Tag did not negatively affect protein expression.  SDS-PAGE showed that 
all MBP variants expressed very well with similar expression levels (Figure 4.1).  No band is 
present at the expected molecular weight in the pre-induction samples (lanes 2, 4, 6, and 8), but a 
band is present at this size in the post-induction sample for each of the variants (lanes 3, 5, 7, and 
9), indicating that the protein is successfully expressed.  Native MBP was used as a control to 
determine the relative expression levels of the claMP-Tagged variants.  Densitometry analysis of 
whole cell lysates indicated that NCC-MBP expressed at similar levels as MBP, whereas 
GNCCG-MBP and MBP-GNCCG exhibited a 10% and 20% decrease in expression, 
respectively.  These observed differences are within the normal batch-to-batch variation in 
 
Figure 4.1  SDS-PAGE analysis of expression of claMP Tag MBP variants. SDS-PAGE confirms 
biosynthetic inclusion of claMP Tag into various positions does not appreciably impact expression of 
MBP.  Coomassie-stained 12% SDS-PAGE gels show the expression of a 40 kDa protein from the 
pET-22b(+)-MBP, pET-22b(+)-NCC-MBP, pET-22b(+)-GNCCG-MBP, and pET-22b(+)-MBP-
GNCCG constructs.  (Lane 1) molecular weight standard, (lanes 2, 4, 6, 8) E. coli lysate of pET-
22b(+)-MBP, pET-22b(+)-NCC-MBP, pET-22b(+)-GNCCGMBP, pET-22b(+)-MBP-GNCCG 
before IPTG induction, (lanes 3, 5, 7, 9) E. coli lysate of pET-22b(+)-MBP, pET-22b(+)-NCC-MBP, 
pET-22b(+)-GNCCGMBP, pET-22b(+)-MBP-GNCCG 4 hours after IPTG induction. 
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expression yields for a single variant and are not appreciably different.  These results confirm 
that insertion of the claMP Tag within a larger protein has a negligible effect on protein 
expression.  
4.3.2  Effects of Metal Insertion Method on Insertion Efficiency 
 The generation of a metal-based bioconjugate requires high efficiency incorporation of 
the metal ion into the metal-binding modality.  The optimal point and method of metal insertion 
are important parameters to investigate when generating a metal-based protein therapeutic and 
are highly dependent on the metal-binding entity.  In this study, the metal-insertion efficiency 
into the claMP Tag was investigated to determine the method of metal insertion and point during 
the purification process that leads to highest yield of the desired metal-bound bioconjugate.  
Whereas most metal-binding modalities are incubated with a salt form of the metal to be 
incorporated,2, 7, 27 the claMP Tag requires transfer of the metal ion from a chelator to achieve the 
desired structure.  Insertion using a chelated metal ion also limits the amount of non-specific 
metal binding to the protein, which has been observed with incubation of MBP with NiCl2.28  It 
has previously been shown that Ni(II) can be successfully inserted into the claMP Tag during 
purification of a His-tagged-protein using Ni-IMAC resin.6  It was also demonstrated that small 
peptides containing the NCC module are rapidly formed using either a resin- or solution-based 
transfer.12-13  In order to avoid metal insertion during the purification step, as occurs with His-
tagged proteins isolated using Ni-IMAC, MBP was selected.  The amylose affinity capture of 
MBP affords the use of a distinct separation scheme that does not involve metals.  This approach, 
therefore, enables determination of the practical ability to separate purification of the claMP 
Tagged protein from the metal incorporation step.  The observed insertion efficiency when metal 
is inserted before or after purification had not been determined previously.  Here, the MBP 
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system permits investigation into the effect of the free thiol moieties on metal incorporation 
efficiency, the potential for intermolecular cross-linking and the ability to include a thiol 
reducing agent in the solution during processing.  Metal insertion efficiencies were investigated 
by incubating the protein with Ni-resin either in the cell lysate prior to purification or after 
elution of the purified protein from the amylose resin.  All MBP variants were examined at 
approximately the same protein concentrations during the metal incubation steps for both 
insertion approaches, thus eliminating a concentration-based bias for the observed metal-
insertion efficiencies.     
Metal-bound and metal-free MBP variants were determined to elute differently on the 
size exclusion column (Figure 4.2). Because Ni(II) incorporation into the claMP Tag causes a 
change in charge of 2-, metal-free variants will elute earlier than metal-bound variants. The 
 
Figure 4.2  SEC separation of claMP-Tagged variants of MBP. Ni-incorporated 
claMP-Tagged MBP variants elute earlier on the size exclusion column than 
unincorporated claMP-Tagged variants, which allows for separation of the two species 
using this method.  Adequate resolution is achieved as Ni-incorporated and 
unincorporated variants elute approximately 15 mL apart at 80 and 95 mL, respectively.   
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charge state of each SEC peak was validated using anion exchange chromatography (AEC), as is 
shown in Figure 4.3.  Metal-free claMP-Tagged variants elute similarly to MBP, whereas Ni-
claMP-Tagged variants elute later in the gradient, indicating that metal is incorporated into the 
tag as they are more negatively charged.  Using the AEC data, it was determined that metal-
bound claMP-Tagged MBP elutes at 80 mL on the SEC, whereas metal-free claMP-Tagged 
MBP elutes later at 95 mL (Figure 4.2).  Because sufficient resolution is achieved, SEC can be 
used to separate metal-bound and metal-free forms of the MBP variants and quantitatively 
determine the yield of the two species.  The metal insertion efficiency for each method of 
insertion is shown in Tables 4.1 and 4.2.  Insertion of metal into the claMP Tag prior to 
purification on the amylose resin leads to a 40% higher yield of metal-incorporated product than 
metal insertion after purification on the amylose resin.  Therefore, metal insertion into the claMP 
Tag is accomplished more effectively in the complex mixture of the cell lysate than when first 
fully purified, whereas the lanthanide binding tags (LBTs), which are also inserted inline within 
a protein sequence, are purified completely before metal insertion.7, 27  Addition of metal-binding 
entities to the antibody surface is also completed after antibody purification,2 but these results 
suggest that metal insertion into the claMP Tag inline within an antibody sequence may be most 
successful when completed before antibody purification using Protein A/G resin.  The high 
incorporation efficiency observed in the cell lysate, where other metal scavenging proteins are 
present, indicates the claMP Tag effectively competes for binding.  SDS-PAGE confirms the 
decrease in metal insertion efficiency observed when Ni(II) is presented after purification is not 
due to disulfide formation among cysteine residues within the tag.  The free thiols within the tag 
are stable and do not become oxidized to form disulfides over the manufacturing time scale.  The 
effect of reducing agents, such as "-mercaptoethanol ("ME), on metal insertion efficiency was 
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also investigated.  For these investigations, metal insertion before purification was performed in 
both the presence and absence of 2.5 mM "ME.  "ME was shown to have a negligible effect on 
metal insertion into the tag, as the insertion efficiencies in the presence and absence of "ME 
were similar (data not shown).  Based on this data set, it is unclear why metal incorporation is 
less effective following purification. 
Table 4.1  Metal Insertion Efficiency Before and After Purification 
Variant Pre-Amylose  Purification 
Post-Amylose 
Purification 
GNCCG-MBP 80.01 36.96 
NCC-MBP 70.33 X 
MBP-GNCCG 66.06 30.87 
*Values reported as the percent Ni-incorporated relative to the overall protein present.  Locations marked with X were not investigated. 
 
Successful incorporation of metal into the claMP Tag requires transfer of the metal from 
a partial chelator to generate the desired complex. It also limits non-specific binding of the metal 
to the protein.  Ni-charged IMAC resin or Ni-NTA was used to accomplish resin or solution 
transfer, respectively.  The insertion efficiency can vary depending on which method is used.  
Figure 4.3  AEC analysis of claMP-Tagged MBP variants. Anion exchange chromatography was used to 
confirm metal insertion into the tag.  The MBP variants without metal bound into the claMP Tag eluted 
similarly to native MBP at 20 minutes (a), whereas the Ni-occupied Ni-claMP-MBP and MBP-Ni-claMP 
proteins (b) eluted later. 
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Resin transfer resulted in approximately 75% yield of the desired metal-incorporated product.  
The one-hour metal incubation time used in these studies is much longer than what is required 
for metal transfer to the tag.  Addition of NiSO4 to the peptide module leads to immediate 
insertion of metal into the tag,13-14 thus suggesting that the results observed with the one-hour 
incubation with the MBP variants are not due to the kinetics of metal-insertion into the tag.    
Because increasing the amount of Ni(II)-resin used during the incubation also had negligible 
impact on insertion efficiencies, the lack of full incorporation is not due to lack of Ni(II) ions for 
coordination.  Rather, the lack of full incorporation may be due to restraints of diffusion within 
the solid resin matrix and/or the protein structure that limit accessibility of the tag to the surface 
of the resin where the nickel is coordinated.  Resin transfer results in a 45% higher yield of the 
desired metal-incorporated product in comparison to solution transfer with Ni-NTA (Table 2).  
Because the chelator on the resin is proprietary and unknown, this result may suggest that metal 
transfer is more efficient when the metal is bound to a solid support or that the proprietary 
chelator better facilitates formation of the claMP complex compared to NTA.  A quantitative and 
kinetic comparison of these processes is not within the scope of this initial assessment, but rather 
the aim here was to establish that metal transfer into the claMP Tag may be accomplished using 
either approach.  
Table 4.2  Metal Insertion Efficiency using either Ni-NTA or Ni-IMAC Resin 
Variant Resin Transfer Solution Transfer 
GNCCG-MBP 75.78 30.07 
NCC-MBP 70.33 X 
MBP-GNCCG 66.06 X 
*Values reported as the percent Ni-incorporated relative to the overall protein present.  Locations marked with X were not investigated.  Metal 




4.3.3  Impact of claMP Tag Placement and Sequence on Insertion Efficiency  
 The tripeptide module responsible for directly binding Ni(II) consists of the Asn-Cys-Cys 
sequence, but residues surrounding this tripeptide can modulate the properties of the claMP Tag 
(unpublished data).  For this reason, the claMP Tag was placed on either the N- or C-terminus of 
MBP to investigate if tag location impacted Ni(II) binding or protein properties.  Because resin 
transfer resulted in a larger yield of the metal-bound product, metal insertion was completed 
using this method to generate a higher yield of the desired product.  As shown in Table 4.1, the 
tag sequence or location does not 
significantly affect the insertion 
efficiency.  GNCCG-MBP has the 
highest insertion efficiency of 80%, 
whereas NCC-MBP and MBP-
GNCCG appear less efficient by 
10% and 14%, respectively.  These 
values are not appreciably different 
because insertion efficiencies varied 
up to 10% from batch-to-batch 
production of the same variant.  
Metal insertion during the lysis step 
would be expected to vary slightly as 
expression levels of each of the variants can vary up to 20% among batches.  Regardless of tag 
placement, Ni(II) is selectively inserted into the tag and the product is primarily monomeric.   
Figure 4.4  Validation of inline Ni-claMP Tag structure. UV-vis 
spectroscopy confirms Ni-insertion into the claMP Tag generates 
the expected structure regardless of tag placement.  Both N- and C-
terminally tagged variants contain features in the visible region near 
418 nm and 530 nm, which are absent in the native protein.  The 
feature typically observed at 310 nm is obscured by the absorption 
of the aromatic side chains of the protein.   
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Ni(II) incorporation into the claMP Tag results in two observable features in the UV-vis 
absorption spectrum at approximately 415 nm and 530 nm (Figure 4.4), due to the S-Ni(II) 
charge transfer and Ni(II) d-d transitions, respectively.12  These features are present in both the 
N- and C-terminally tagged variants, indicating the Ni(II) is incorporated regardless of tag 
placement.  A feature at approximately 315 nm also is indicative of Ni(II) incorporation, but 
because the absorbance of this band is substantially lower than the total absorbance of the 38 
aromatic residues within MBP, this feature is obscured in the MBP variants.  Non-reducing SDS-
PAGE confirms that the product is primarily monomeric indicated by the large band at 37 kDa 
with approximately 3% and 6% dimeric species observed at 75 kDa for Ni-claMP-MBP and 
MBP-Ni-claMP, respectively (Figure 4.5).  Because these bands are not present in the reducing 
SDS-PAGE gel, the larger molecular weight species must be due to aberrant disulfide bond 
formation among the cysteine residues of the claMP Tag.  Omission of "ME from the lysis 
 
Figure 4.5  Analysis of intermolecular cross-linking.  Non-reducing and reducing SDS-PAGE confirm 
the Ni-claMP variants do not readily undergo intermolecular disulfide bond formation.  Ni-claMP-MBP 
and MBP-Ni-claMP samples contain approximately 6% and 2% dimer, respectively.  (Lanes 1 and 5) 
molecular weight markers (Bio-Rad Precision Plus Protein Dual Color Molecular Weight Standard), 
(lanes 2 and 6) purified MBP, (lanes 3 and 7) purified Ni-claMP-MBP, and (lanes 4 and 8) purified MBP-
Ni-claMP.  Lanes 2, 3, and 4 contain the non-reduced samples, and lanes 6, 7, and 8 contain the reduced 
samples.  Position of dimer is indicated by the arrow. 
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buffer did not result in substantially higher amounts of dimer formation, suggesting that the 
reducing agent does not contribute appreciably to limiting dimer formation.   
4.3.4  MBP Surface Charge Reliant on claMP Tag Location 
Even though the site of tag placement does not alter metal insertion efficiency, it does 
impact the surface charge profile of the molecule.  Incorporation of Ni(II) into the claMP Tag 
generates a complex with an overall charge of 2- and addition of this entity to MBP, which has an 
overall charge of 10-, leads to a charge of 12- for the Ni-claMP-Tagged MBP variants.  The 
effects of claMP Tag location on molecule surface charge were investigated using AEC.  Non-
tagged MBP elutes 20 minutes into the gradient, whereas the Ni-claMP-Tagged MBP variants 
elute later in the gradient, indicating their more negative surface charge.  MBP-Ni-claMP elutes 
as one clean peak at 40 minutes, whereas Ni-claMP-MBP elutes up to five minutes earlier and 
contains multiple peaks (Figure 4.3b).  The elution of both variants much later in the gradient 
than native MBP confirms Ni(II) is incorporated into the tag, but the presence of multiple peaks 
in the chromatogram of the N-terminally tagged variant suggests that the composition and/or 
structural features surrounding the claMP tag in this position may impact the structure and/or 
conformational dynamics through local surface charge differently.  The surface charge of the 
molecule, though, is altered by claMP Tag location.  The Ni-claMP-Tagged variants elute later 
in the AEC chromatogram than MBP, which was expected because Ni(II) insertion into the 
claMP Tag causes a change in charge of 2-.  The peak profile is altered depending on claMP Tag 
placement, which may reflect differences in the construct’s ability to tolerate higher salt 
concentrations because both behave identically when analyzed by SEC.  The N-terminus of MBP 
contains a single Lys residue embedded within a large region of negatively charged surface area 
(Figure 4.6) and is also highly flexible with no distinct structural elements.26  Placement of the 
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negatively charged Ni-claMP complex within a region of high negative charge may cause charge 
repulsion between the complex and the surface of the protein or differential charge shielding of 
the complex by the protein surface, resulting in a less compact, more dynamic structure when 
placed in this position.  Alterations in the salt concentration can alter the charge shielding effects, 
which would affect the surface charge of the molecule and alter the retention time on the anion 
 
Figure 4.6  Electrostatic surface map of MBP.  Placement of the Ni-claMP Tag on the 
N- or C-terminus causes different effects on the surface charge of the molecule due to the 
local charge near these regions (a).  The N-terminus contains a single lysine surrounded by 
a large region of negatively charged surface area (b), and the C-terminus has larger 
patches of positively charged surface area (c).  The different surface charges observed in 
these regions will alter the interactions between the Ni-claMP complex and the protein 
surface.  N- and C-terminal residues are denoted by a yellow asterisk.   
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exchange column.  The C-terminus of MBP is both more structured and more basic in character.  
As such, MBP may accommodate the additional negative charge well in this position and its 
overall structure be less affected by increased salt concentration.  A high degree of flexibility 
within the N-terminal region may cause slight variations in surface charge due to the mobility of 
this segment, but the structural restrictions of the C-terminal region would lead to a more 
constant surface charge.  The surface charge of antibodies is also differentially affected by 
protein structure, as multiple charge states are observed with modification of a single lysine 
within an antibody, depending on the position of the residue within the protein structure.29  Here, 
the data shows placement of the claMP Tag at the C-terminus of MBP to be a better choice than 
at the N-terminus.   
Because the N- and C-terminally tagged MBP variants exhibited different AEC elution 
profiles, the effect of ionic strength on the structural stability of the variants was examined.  
Thermal titration of MBP, Ni-claMP-MBP, and MBP-Ni-claMP was performed at three different 
ionic strength values corresponding to the AEC retention times of the three variants, which are 
142 mM, 252 mM, and 272 mM ionic strength, respectively.  MBP contains a characteristic !-
helical fold,26 which allows for protein unfolding to be monitored at 222 nm.  At all ionic 
strength values, the three variants exhibited similar onset temperatures for unfolding (Tm,onset).  As 
the Tm,onset has been reported to be indicative of the physical stability of ADCs,9 similar values for 
all MBP variants suggests that addition of the Ni-claMP Tag to MBP does not impact the 
physical stability of the molecule.  MBP-Ni-claMP does contain two separate unfolding 
transitions that are clearly evident at lower ionic strength (Figure 4.7a).  At low ionic strength, 
MBP and Ni-claMP-MBP do not unfold to the extent observed at higher ionic strength, but the 
second transition seen with MBP-Ni-claMP at lower ionic strength does result in a similar degree 
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of unfolding as observed at higher ionic strength conditions (Figure 4.7b).  Therefore, the 
different AEC profiles observed with the two tagged variants may be caused by greater 
interaction between the cationic resin and C-terminally tagged variant, as this variant may be 
more unfolded at higher ionic strength leading to exposure of additional charged residues.  MBP-
Ni-claMP exhibited similar melting temperatures as native MBP (Table 4.3); however, the 
melting temperature of Ni-claMP-MBP is 3-4 °C lower than the other variants.  MBP contains a 
large degree of negatively charged surface area in the N-terminal region (Figure 4.6b), which 
may lead to charge repulsion between the protein surface and negatively charged Ni-claMP 
 
Figure 4.7  CD thermal plot of MBP variants.  a)  At low ionic strength (142 mM), the unfolding curve of 
MBP and N-terminally-tagged MBP are very similar and contain one transition, whereas the C-terminally-
tagged variant contains two distinct transitions and a larger extent of unfolding.  b)  At higher ionic strength 
conditions (272 mM), a similar degree of unfolding occurs with MBP and the N-terminally-tagged variant as 
was observed for the second transition of the C-terminally-tagged variant at low ionic strength. 
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complex and structural destabilization.  Increasing the ionic strength also minimally affects the 
Tm of claMP-Tagged bioconjugates, but has been shown to adversely affect the structural 
stability of ADCs,22 suggesting that an inline claMP-Tagged bioconjugate may be more 
amenable to alterations in solution conditions.  
Table 4.3  Effect of Ionic Strength on Tm of MBP Variants 















142 50.9, 68.1a 
252 56 
272 55.5 
aTwo values reported due to the two transitions that occur with this variant at the specific ionic strength. 
 
4.3.5  MBP-Ni-claMP versus EDTA Competition Analysis 
 The effectiveness of a metal-based bioconjugate depends on the ability of the metal-
binding modality to retain the metal in the presence of competitive agents.  To investigate the 
relative binding strength of the claMP Tag for Ni(II), MBP-Ni-claMP was incubated with a ten-
fold molar excess of EDTA (10 mM) and the percent retention of Ni-claMP Tag over one week 
was determined.  EDTA has extremely high affinity for Ni(II), which is on the order of 1018 
under the conditions utilized.30  This concentration of EDTA was chosen as a practical starting 
concentration because biological preparations generally do not contain concentrations higher 
than 10 mM EDTA.  The proteins also were incubated with a 100-fold molar excess of EDTA.  
The objective of this initial experiment was not to establish a competitive binding constant, but 
rather to evaluate the loss of metal from the claMP Tag when a high-affinity chelator is present.  
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Ni(II) incorporation into the claMP Tag leads to the presence of multiple unique features within 
the UV-vis absorption spectrum, which allows for the percent retention to be assessed 
quantitatively (Figure 4.7a).  If nickel is lost to EDTA, the intensity of Ni-claMP Tag signal 
between 310-550 nm will decrease proportionally, and a much weaker peak will emerge near 
700-800 nm, which reflects Ni-EDTA complex formation.  The peak height of the features at 
418 nm and 530 nm were used to quantitatively assess Ni(II) incorporation into the claMP Tag.  
Analysis of both the N- and C-terminally tagged variants indicates that incubation with either 
concentration of EDTA leads to a linear decay in intensity of these features with differences in 
Ni(II) retention based upon claMP Tag placement.  Ni(II) retention by the claMP Tag in the C-
terminally-tagged variant decreases by approximately 9% after seven days (Figure 4.8a), and the 
N-terminally-tagged variant exhibits greater Ni(II) loss from the tag with a two fold larger 
decrease observed at 100 mM EDTA in comparison to 10 mM EDTA.  AEC was also used to 
qualitatively assess metal retention in the claMP Tag by monitoring the peak profile to determine 
if any differently-charged variants emerge due to Ni(II) loss from the tag.  As shown in Figure 
4.8b, the peak profile of the C-terminally-tagged variant remains unchanged after 7 days, further 
confirming that the metal is not easily chelated from the claMP Tag by EDTA in this variant.  
The larger decreases in metal retention for the N-terminally-tagged variant indicate that the 
protein elements modulate the release rate, as repulsion between the negatively charged N-
terminal region of MBP and the Ni-claMP complex may cause the metal to be more easily 
chelated from the claMP Tag than the C-terminally-tagged variant.  The positively charged C-
terminal region of MBP may stabilize the complex through electrostatic interactions, hence 
making metal chelation from the tag more difficult.  EDTA competition experiments have been 
performed with the organic-based metal-binding agents in complex with lanthanide ions, and 
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EDTA is able to compete effectively for and chelate the metal from the metal-binding entity 
within minutes when added at an equivalent molar ratio or two-fold excess.31-32  Metal loss from 
the claMP Tag does not occur that quickly in the presence of ten- and 100-fold excess of EDTA, 
suggesting that the claMP Tag is advantageous in comparison to organic-based metal-binding 
modalities that are commonly used in therapeutic and imaging applications.   
 
Figure 4.8  Evaluation of metal retention in Ni-claMP Tag.  EDTA competition analysis confirms that Ni(II) is 
not easily chelated from the claMP Tag in the presence of 10 mM EDTA.  a)  The UV-vis spectrum of MBP-Ni-
claMP retains similar intensity and features as initially observed suggesting that the metal is retained by the claMP 
Tag.  The peak intensity at 418 and 530 nm in the UV-vis spectrum was used to quantitatively determine percent 
incorporation over the one-week time period, with approximately a 9% decrease in metal retention observed after 
one week with both concentrations of EDTA.  b)  AEC also indicates that Ni(II) remains incorporated within the 
claMP Tag in the presence of EDTA.  The peak at 40 minutes corresponds to MBP-Ni-claMP and the peak profile 
does not change appreciably over the time period investigated. 
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4.4  CONCLUSION  
 Use of the claMP Tag as an inline metal-binding modality requires optimization of 
different parameters to determine the method that results in the highest yield of the desired 
metal-incorporated product.  In this investigation, it was determined that the highest metal 
insertion efficiency into the tag is achieved when metal is presented immediately after cellular 
lysis via a chelator attached to a solid support.  The site of tag placement within the protein 
sequence and the size of the protein used have minimal effects on the insertion efficiency, but the 
charge profile of the region surrounding the claMP Tag can lead to differential surface charge 
effects and influence the behavior of the conjugate.  Placement of the Ni-claMP complex on the 
N-terminus of MBP led to a slight decrease in structural stability in comparison to C-terminal 
placement.  Finally, retention of Ni(II) by the claMP Tag in the presence of large excesses of 
EDTA was shown to be influenced by site of tag placement, with the C-terminally-tagged variant 
retaining metal binding more effectively than the N-terminally-tagged variant.  Therefore, the 
stability of the Ni-claMP complex is modulated by nearby protein elements.  The successful 
application of the claMP Tag within a second, unrelated protein system further confirms the 
applicability of the tag as a platform to enable targeted metal delivery. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
5.1  MAJOR CONCLUSIONS 
 This work details the first application of the claMP Tag as a metal-binding tag in the 
context of larger protein systems.  The claMP Tag is able to be inserted inline within the gene of 
the desired protein, which allows for the formation of the bioconjugate as one molecule, 
eliminating the need for complex chemical conjugation chemistry.  Insertion of the cysteine-
containing claMP Tag into the EGF sequence does not adversely affect expression or disulfide-
bond formation within this protein system.  When Ni(II) is selectively inserted into the claMP 
Tag, the SOD-like activity of the Ni(II)-claMP complex is maintained in the presence of the 
protein, and importantly, Ni(II) remains incorporated within the tag in the presence of a high –
affinity competitive chelator.  Finally, the stability analysis of the EGF-Ni-claMP Tag conjugate 
confirms that the claMP Tag module is structurally and chemically stable for months when 
stored in solution and the metal-occupied tag does not adversely impact the physicochemical 
stability of the protein to which it is attached.  These studies illustrate the great potential for use 
of the claMP Tag for targeted delivery of metal ions.      
5.2  FUTURE DIRECTIONS 
5.2.1  Confirming Cause of Conjugate Cleavage  
During the stability analysis of EGF-Ni-claMP, a cleavage event was observed to occur 
between residues Leu52 and Arg53 within EGF and results in release of Arg53-Ni-claMP from 
the C-terminus of the protein.  Over the time period investigated, the cleavage event could only 
be observed in KPi, but not Tris-Cl, suggesting that it may be buffer-mediated or due to the 
presence of a contaminant, such as residual protease and/or extraneous metal species, because 
even high-quality phosphate is known to contain trace metals.  Although excess EDTA did not 
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diminish retention of nickel in the tag, it also remains possible that phosphate plays a role in 
alteration of the tag over long time periods.  Therefore, all analyses should be completed in both 
buffer systems to control for the influence of buffer on the cleavage event.  Although the exact 
cause of this cleavage event has not yet been determined, further experiments could be 
conducted to elucidate the reason for this occurrence.  First, possible protease contamination 
could lead to hydrolysis of the peptide backbone preceding Arg53.  Both chymotrypsin and 
pepsin have been shown to cleave C-terminal to Leu residues,1 which is the amino acid 
immediately preceding the cleavage site.  If cleavage were due to protease contamination, 
addition of an appropriate protease inhibitor could slow generation of these species and the 
possibility of cleavage.   
Metal-catalyzed cleavage of peptide bonds has also been reported.2-4  Metal-induced 
oxidative damage resulted in oxidation of the amine moieties, whereas the carboxyl end 
remained intact.4  Our mass spectrometry results of the EGF fragment also are consistent with 
this type of mechanism, but because we could not detect the Arg53-Ni-claMP fragment to 
confirm modification of the amine group, the current data set cannot distinguish between a 
hydrolytic and oxidative cleavage mechanism.  Ni(II)-induced hydrolysis of the peptide 
backbone is also a possibility.  This type of cleavage is sequence specific and, in all published 
reports of which we are aware, requires an embedded His residue.2  Complete cleavage via this 
mechanism occurs at a constant linear rate and in a substantially shorter time frame, which is in 
contrast to our system that undergoes a long lag period before degradation begins.  These studies 
were completed at 37-60 °C so it would be interesting to determine if incubation of EGF-Ni-
claMP at higher temperatures would expedite the cleavage event.  Rates of Ni(II)-induced 
cleavage have been shown to increase as a function of temperature5 so incubating EGF-Ni-
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claMP at elevated temperature would cause the cleavage event to occur at a greater rate.  
Insertion of varying polypeptide sequences containing the C-terminal region of EGF and the Ni-
claMP complex into other proteins, such as MBP, and adjacent sequences could be used to 
investigate whether this cleavage event is specific to the EGF formulation or if the Ni-claMP 
complex is capable of performing peptide backbone cleavage.  The specific spacing/residue 
requirements for cleavage could also be determined.  If the Ni-claMP complex is capable of 
performing metal-induced peptide backbone cleavage, the Ni-claMP complex could be applied 
as a non-enzymatic method for removal of affinity tags, as is reported for the SHHK peptides.6  
Peptide controls could also be evaluated to determine the mechanism by which this cleavage 
reaction proceeds.  Polypeptide sequences containing the last 8-10 residues of EGF and the Ni-
claMP complex on the C-terminus could be incubated at both 4 °C and 50 °C and then analyzed 
using AEC and mass spectrometry.  Mass spectrometry analysis of the cleaved fragments could 
confirm whether oxidative cleavage or hydrolysis occurs because different masses would be 
observed for the C-terminal fragment in each mechanism.  Performing the analysis in both buffer 
systems also will allow for evaluation of the buffer-dependency of the cleavage event.  To 
determine if the reaction is dependent on released Ni(II), excess molar equivalents of NiSO4 
could be added to the Ni-claMP-Tagged polypeptide.  If the cleavage event is dependent on free 
Ni(II), the rate should increase with increasing NiSO4 concentration.  
We also hypothesize that the peptide fragment exhibits lower solubility upon cleavage, 
causing it to crash out of solution.  Determining the time-dependent solubility of a control 
peptide could be used to support or disprove this hypothesis.  Forming the Ni-claMP complex 
within the RGNCCG peptide or N-terminally amidated RGNCCG in both Tris-Cl and KPi and 
monitoring its solubility over time using the distinctive Ni-claMP features present within the 
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UV-vis absorption spectra could be used to evaluate the solubility.  The effect of peptide 
concentration of solubility could also be examined by assessing the solubility of the R-Ni-claMP 
complex at varying concentrations.    
5.2.2  Probing Necessary Storage Conditions for claMP-Tagged EGF 
 In the stability studies completed here, the EGF-Ni-claMP conjugate was stored in 
aqueous conditions at 4 °C, but it would be desirable to store the conjugate in lyophilized form 
because this typically increases shelf life substantially.  Many proteins are prone to physical 
and/or chemical degradation when formulated in aqueous solutions, which may be exacerbated 
by the stresses experienced during product handling, such as temperature excursions and 
excessive agitation.7  The presence of a metal ion may also cause adverse effects on the stability 
of a claMP-Tagged bioconjugate.  Various metal ions such as Cu(II), Zn(II), and Ni(II) lead to 
cleavage within the hinge region of the IgG1 molecule,3 and oxidative cleavage of the peptide 
backbone has also shown to occur in the presence of metal ions.4  Therefore, formulation of a 
claMP-Tagged bioconjugate as a lyophilized product may be required to limit chemical and 
physical degradation events and achieve the two-year average shelf-life necessary for protein 
therapeutic products. 
 Even though storage of therapeutics in a lyophilized form assists in achieving the 
required shelf life, there are many factors that must be considered when developing a lyophilized 
formulation, as opposed to an aqueous formulation.  The lyophilization process contains three 
distinct steps –freezing, primary drying, and secondary drying – during which degradation of the 
protein product can occur.  Suitable excipients, such as sucrose or trehalose, must be chosen to 
stabilize the protein during these extreme stresses, as many protein therapeutics are at least 
partially denatured during the lyophilization process in the absence of stabilizing agents.7  
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Because stabilization of protein therapeutics through lyophilization is widely reported, the 
generation of a lyophilized formulation of a claMP-Tagged bioconjugate may help improve 
stability of the protein and/or inhibit possible metal-dependent degradation of the conjugate.    
5.2.3  Production and Characterization of Inline claMP-Tagged Antibody Conjugate  
 The “big picture” goal for application of the claMP Tag within protein systems is the 
formation of a claMP Tag-based antibody drug conjugate (ADCs) for use in targeted therapy and 
diagnostic imaging. Therapeutic ADC entities are capable of site-specific delivery of cytotoxic 
drugs, such as MMAE to treat cancer,8-9 or because over 50% of all cancer patients receive a 
platinum-based drug, in the context of claMP-Tagged conjugates, Pt(II).  In this work, Ni(II) was 
inserted into the claMP Tag, but other metals, including Pt(II), are capable of being inserted into 
the claMP Tag (unpublished data).  The first step in producing a claMP Tag-based ADC is 
insertion of the claMP Tag within the antibody sequence.  Antibodies are very complex 
molecules with distinct structural elements required for protein function and stability, but 
acquiring high-resolution data is challenging due to the size of these molecules.  Therefore, it is 
difficult to assess the most desirable site for claMP Tag insertion within the protein sequence.  
Molecular modeling can be used to investigate the effects of claMP Tag addition on structural 
elements, but the experimental methods for investigating local structural alterations that may 
occur due to claMP Tag addition are limited.  Evaluating the physical stability of the ADC in 
comparison to the native molecule is the most common method used to assess the effect of 
conjugation on antibody structure.10-11   
 Determining the drug-to-antibody ratio (DAR) is an important step in ADC 
characterization.  This can be assessed using UV-vis absorption spectroscopy because the drug 
entity absorbs at a wavelength distinct from the antibody.12  Quantitation of the DAR of Pt-
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claMP Tag-based ADCs is not possible using this method due to extensive overlap of the 
absorption from the antibody and Pt-claMP complex.  Mass spectrometry and hydrophobic 
interaction chromatography are also commonly used to determine the DAR.  Characterization of 
claMP Tag-based ADCs requires different methods than typical ADCs due to the unique 
properties of the system.  The drug entity in typical ADCs is a hydrophobic molecule, whereas in 
our system, it is a negatively charged complex containing a Pt(II) ion.  Incorporation of Pt(II) 
into the claMP-Tagged antibody leads to a change in charge of the conjugate.  Even though this 
may be very small, a slight shift in the AEC chromatogram would suggest successful metal 
incorporation.  ICP-OES, which is much more quantitative, is the best method to use for the 
accurate determination of the DAR of a Pt-claMP Tag-based ADC.  Although Pt(II) has been 
widely used as a therapeutic entity in the form of cisplatin, it exerts no specificity in the cell type 
that it attacks causing death of both healthy and diseased cells.  Successful generation of a claMP 
Tag-based ADC would be highly advantageous as a chemotherapeutic agent, as it would allow 
for site-specific delivery of Pt(II) with the desired target being modulated by the antibody 
selected.   
 There exists great potential for application of the claMP Tag as a bioconjugate for use in 
both therapeutics and imaging, but the bioconjugate must be stable for at least the two-year shelf 
life.  By determining the exact cause and mechanism of the cleavage event that occurred with the 
EGF-Ni-claMP conjugate, the buffer conditions can be modulated to limit cleavage and/or a 
small amount of EDTA could be added to control metal-dependent cleavage, either chemical or 
enzymatic, deriving from either the buffer or release from the tag.  Storage of the claMP-Tagged 
bioconjugate as a lyophilized product may also assist achieving the desired product shelf life, but 
the parameters concerning successful lyophilization of the metal-claMP complex while retaining 
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metal binding must also be assessed.  Although not desirable for formation of a claMP-Tagged 
bioconjugate, if the Ni-claMP complex is determined to cause peptide backbone hydrolysis, the 
Ni-claMP complex could be used in affinity tag removal from proteins.  The results from these 
additional studies will assist in determining the design space around the claMP Tag system for 
use as a biotechnology tool.    
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